

# Choices and Outcomes in Assignment Mechanisms: The Allocation of Deceased Donor Kidneys<sup>\*†</sup>

Nikhil Agarwal, Charles Hodgson, Paulo Somaini<sup>‡</sup>

## Abstract

While the mechanism design paradigm emphasizes notions of efficiency based on agent preferences, policymakers often focus on alternative objectives. School districts emphasize educational achievement, and transplantation communities focus on patient survival. It is unclear whether choice-based mechanisms perform well when assessed based on these outcomes. This paper evaluates the assignment mechanism for allocating deceased donor kidneys on the basis of patient life-years from transplantation (LYFT). We examine the role of choice in increasing LYFT and compare equilibrium assignments to benchmarks that remove choice. Our model combines choices and outcomes in order to study how selection affects LYFT. We show how to identify and estimate the model using instruments derived from the mechanism. The estimates suggest that the design in use selects patients with better post-transplant survival prospects and matches them well, resulting in an average LYFT of 8.78, which is 0.92 years more than a random assignment. However, the maximum aggregate LYFT is 13.84. Realizing the majority of the gains requires transplanting relatively healthy patients, who would have longer life expectancies even without a transplant. Therefore, a policymaker faces a dilemma between transplanting patients who are sicker and those for whom life will be extended the longest.

---

<sup>\*</sup>This version: December 2, 2022. We are grateful to UNOS for facilitating access to the data. We thank Peter Hull, Adam Kapor, Ariel Pakes, Daniel Waldinger, and seminar participants at several universities and conferences for helpful comments and feedback. We benefited from multiple discussions with Yusuke Narita during early stages of the project. Andrew Komo, Raymond Lee, and Lingjun (Lotus) Xia provided excellent research assistance. The authors acknowledge support from the National Science Foundation (SES-1948714) and the Alfred P. Sloan Foundation (FG-2019-11484).

<sup>†</sup>The data reported here have been supplied by UNOS as the contractor for the Organ Procurement and Transplantation Network (OPTN). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the OPTN or the U.S. Government.

<sup>‡</sup>Agarwal: Department of Economics, MIT, and NBER, email: agarwaln@mit.edu. Hodgson: Department of Economics, Yale University, email: charles.hodgson@yale.edu. Somaini: Stanford Graduate School of Business and NBER, email: soma@stanford.edu.

# 1 Introduction

Assignment mechanisms are commonly used to allocate scarce resources. Examples include public schools, public housing, and organ allocation. While the design of these mechanisms takes choice-theoretic notions of efficiency as a primary objective (Roth and Sotomayor, 1992; Abdulkadiroglu and Sonmez, 2003), this desideratum often differs from the goals of policymakers – school districts emphasize student achievement and organ transplant systems emphasize patient survival.

Because canonical choice-based mechanisms are not designed to optimize these outcomes, they may not perform well on these dimensions. Agents’ choices may not be well-informed and co-ordination failures may undercut this objective.<sup>1</sup> If so, a planner who can dictate assignments based on estimated benefits may be able to do better. However, agents may also have private information about the likely outcomes and using a choice-based mechanism may serve policymakers’ objectives.

This paper evaluates the mechanism used to allocate deceased donor kidneys on the basis of survival outcomes. We compare the performance and distributional consequences of the mechanism to alternative assignments. Our benchmark assignments investigate whether maximizing survival is in conflict with distributional concerns (Atkinson, 1970) or prioritarianism which targets the sickest or neediest (c.f. Persad et al., 2009; Waldinger, 2017). We also assess the role of choice by examining its relationship to survival and considering alternatives that dictate assignments using observables alone.

We make several contributions in service of this objective. We present the first quasi-experimental estimates of the Life-Years from Transplantation (LYFT), defined as the difference between median survival with and without a transplant, as a function of patient/donor-specific observed and unobserved characteristics. The current state-of-the-art in the medical literature relies on observational approaches (Wolfe et al., 2008), in part because conducting randomized control trials is both challenging and creates ethical issues. We use insights from the literature on generalized Roy selection to analyze a joint model of choices and outcomes in

---

<sup>1</sup>Moreover, in the kidney allocation context, surgeons who advise patients may suffer from agency problems that can misalign decisions relative to maximizing survival outcomes.

an assignment mechanism. In contrast to the standard framework with multiple treatments (e.g. [Lee and Salanie, 2018](#); [Heckman and Pinto, 2018](#)), assignment contexts often do not have a small number of treatments, in our case because each donor is unique. We therefore model potential outcomes as a function of patient, donor and match-specific characteristics, some of which are unobserved. Our results show how to identify and estimate the effects of counterfactual assignments by using variation in offers made to patients and choice shifters that are excluded from outcomes.

Deceased donor organs are a scarce and valuable resource. Only a sixth of the approximately 100,000 patients waiting for a kidney are transplanted annually, and thousands die while waiting.<sup>2</sup> Increasing LYFT is an important policy goal: transplantation committees use observational estimates of LYFT to evaluate proposed reforms.<sup>3</sup> When a kidney becomes available, patients on the waitlist are offered the organ in a priority order. Patients, or surgeons acting on their behalf, may choose to reject an offer and instead wait for a future organ. This decision may depend on the perceived benefits of a transplant from the offered organ.

We jointly model acceptance decisions and survival outcomes to incorporate the potential for selection. The first component of our model considers the choices patients make; the second and third components respectively model patient untransplanted survival and post-transplant survival with the offered organ. These models use a rich set of patient and organ attributes as well as time to treatment. Given our focus on evaluating alternative assignments, we also include patient- and patient-donor level unobservables.

Identification of the model is challenging because transplanted patients can be selected on untransplanted survival, post-transplant survival from an average kidney, or patient-kidney match-specific survival. Selection on these margins can be induced both because choices can depend on survival prospects and because patient waiting time is prioritized in the mechanism.

---

<sup>2</sup>See <https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/>.

<sup>3</sup>Reports to the OPTN Kidney Transplantation Committee generated by the Scientific Registry of Transplant Recipients (SRTR) of alternative designs use average LYFT as a summary measure of performance. The committee’s meeting minutes indicate that this measure is focal. In fact, the U.S. has considered a priority system based on LYFT in the past, and the U.K. uses a “transplant benefit score” to allocate kidneys ([Watson et al., 2020](#)).

We identify our model by combining two sources of variation. The first source is randomness in the offers made to a given patient, conditional on the patient’s priority-type in the mechanism. It allows us to compare the survival outcomes of patients whose final assignments differed due to the organs they were offered. Using standard arguments (e.g. [Imbens and Angrist, 1994](#)), we show that this instrument identifies a treatment effect for the select group of patients whose assignment is affected by an offer.

An important limitation of this estimand is that it does not allow us to predict survival from counterfactual assignments. It cannot consider changes in the set of patients who are transplanted or changes in the kidneys to which a patient is matched. To fill this gap, we first use novel arguments to identify our choice model. We then show that a continuous shifter of choices that is excluded from outcomes can be used to identify the effects of alternative assignments. Related approaches have been used in other settings by [Geweke et al. \(2003\)](#); [Heckman and Navarro \(2007\)](#); [Lewbel \(2007\)](#); [Hull \(2018\)](#) to correct for selection and to estimate marginal treatment effects ([Heckman and Vytlačil, 2005](#)). Our choice shifter is based on organ scarcity controlling for geography and time. We estimate the model using a Gibbs’ sampler similar to [Geweke et al. \(2003\)](#).

Our estimates suggest that choices and assignments are positively correlated with survival outcomes due to both observed and unobserved factors. Patients are more likely to accept kidneys that result in longer survival and those with match-specific benefits. Partly because of this, transplanted patients have a higher LYFT from the average organ as compared to untransplanted patients. Thus, prior approaches that do not account for selection on unobservable factors (e.g. [Wolfe et al., 2008](#)) yield biased estimates.

Next, we benchmark the observed assignment from the perspective of a utilitarian planner who’s objective is to maximize LYFT. We focus on survival effects because it is a focal outcome for kidney allocation, and compare the observed assignment to alternatives ranging from a random assignment to one that maximizes LYFT. Because distributional constraints may limit the ability to select which patients get a transplant, we also consider alternatives that re-assigns organs while fixing the set of transplanted patients. Finally, we measure the LYFT increase that can be achieved by a planner who can dictate assignments based only on observed patient and donor characteristics.

The observed assignment produces higher LYFT than random allocation – 8.78 years versus 7.87. Most of this gain comes from allowing patient choice. Assignment to patients based on existing priority rules without allowing for choice only achieves an average LYFT of 8.01. The drop from the observed assignment suggests that choice may not be dispensable if the unobserved types are private information.

But, there is significant room for improvement – the maximum possible LYFT given the available organs is 13.84. The increase comes from selecting patients who benefit more from the transplant and matching these patients to donors who are more suitable for them. A significant portion of these gains can be achieved if a planner can dictate assignments using observables in our dataset.

These potential improvements in LYFT have important distributional consequences that may present real-world challenges. Although a priori unclear because the sickest may also have benefited the most from a transplant, increasing LYFT requires transplanting patients who would have lived longer without a transplant because LYFT and survival without a transplant are strongly correlated. Such re-distribution creates distributional concerns because it increases the dispersion in remaining life-years ([Atkinson, 1970](#)). While some medical ethicists may still support maximizing total survival benefits especially in the presence of scarce resources, others consider worst-off prioritarianism for the sickest as important (see [Persad et al., 2009](#), and references therein). Our results indicate that the planner faces a dilemma between these two goals.

*Related Literature:* We provide an alternative perspective for evaluating assignments to the literature studying assignment mechanisms, which typically focuses on revealed preference based measures. ([Roth and Sotomayor, 1992](#)).<sup>4</sup> For example, the theory of school choice typically bases welfare on student preferences ([Abdulkadiroglu and Sonmez, 2003](#)), and the empirical literature uses a willingness to travel measure for welfare comparisons (see [Agarwal and Somaini, 2020](#), for a survey).

---

<sup>4</sup>[Robinson-Cortes \(2019\)](#) is an early exception that assumes that social workers minimize disruptions when placing children into foster care. A recent set of papers, released after our work, consider the effects of changes in assignment systems on downstream outcomes, mostly in education markets. [Kapor et al. \(2020\)](#); [Otero et al. \(2021\)](#) and [Larroucau and Rios \(2022\)](#) study student achievement effects of, respectively, expanding college admission platforms, affirmative action policies and reapplying to college; and [Bates et al. \(2022\)](#) study teacher assignment.

Instead of survival outcomes, the economics literature on organ donation focuses either on the number of transplants (e.g. [Teltser, 2019](#); [Dickert-Conlin et al., 2019](#)) or on decision-theoretic notions of welfare ([Agarwal et al., 2021](#)), with an influential literature focusing on expanding living donor kidney exchange (e.g. [Roth et al., 2004](#); [Agarwal et al., 2019](#)). Yet, the vast majority of kidney transplants come from deceased donor organs.

Our paper also relates to approaches that leverage quasi-experimental variation in school choice mechanisms to estimate school quality either arising from tie-breakers (e.g. [Cullen et al., 2006](#), [Abdulkadiroglu et al., 2017](#)) or from instruments that shift assignment probabilities (e.g. [Abdulkadiroglu et al., 2020](#)). This literature either estimates a local average treatment effect, which is not sufficient for analyzing outcomes from counterfactual assignments because of changes in the set of compliers, or value-added for a school, which abstracts away from match-specific effects. Our approach combines quasi-random variation in assignments with a choice shifter to simultaneously solve both issues. In contemporaneous work, [Kapor et al. \(2020\)](#) use this message of our paper to study outcomes in a college admissions setting.

The techniques we use build on a large literature studying selection models ([Roy, 1951](#)). Our model is related to models that combine outcomes with choice models to correct for selection when estimating treatment effects ([Geweke et al., 2003](#); [Heckman and Navarro, 2007](#); [Lewbel, 2007](#); [Hull, 2018](#)), causal survival models ([Abbring and den Berg, 2003](#)), and models of multi-valued treatments ([Lee and Salanie, 2018](#); [Heckman and Pinto, 2018](#)). The main difference relative to these papers is that patients may have match-specific benefits from an organ, resulting in a large number of unique treatments. This issue is important in assignment contexts whenever there are a large number of heterogeneous objects. We address it by using a model with rich observed heterogeneity across objects and unobserved heterogeneity in outcomes along three dimensions – baseline outcomes, average outcomes given observable characteristics of the transplanted organ, and match-specific effects – with each dimension correlated with unobservables in the choice model.

*Overview:* Section 2 describes the institutions and the data. The model and the instruments are described in Sections 3 and 4. Section 5 presents the identification results and the empirical model. The estimates, LYFT in the observed mechanism and counterfactuals are in Sections 6, 7 and 8 respectively.

## 2 Background, Data, and Descriptive Evidence

### 2.1 Institutional Features

*Basics of Kidney Transplantation:* Approximately 750,000 patients are afflicted with End-Stage Renal Disease (ESRD) in the United States (USRDS, 2018). Medicare provides near universal coverage for costs related to ESRD, irrespective of age, costing the taxpayer \$35.4 billion in 2016 (7.2% of Medicare claims (USRDS, 2018), approximately 1% of the federal budget).

Transplantation is considered the best treatment for ESRD. Each transplant is estimated to extend a patient’s life by several years (Wolfe et al., 2008) while also saving between \$195,000 – \$400,000 in dialysis costs (Irwin et al., 2012; Held et al., 2016). These estimates are based on survival models and comparisons of healthcare costs with and without a transplant. We improve on the former set of estimates by using quasi-experimental variation.

There is significant potential for heterogeneity in survival effects, even amongst compatible patient-donor pairs (Danovitch, 2009). First, survival both with and without a transplant can differ across patients. Some patients tolerate dialysis better than others and co-morbidities influence post-transplant survival prospects. Second, donor quality – circumstances of the donor’s death, kidney function, and the donor’s health prior to death – can significantly influence transplant outcomes. Finally, there may be match-specific factors that affect post-transplant survival. Examples include size and weight match as well as tissue-protein similarity between patient and donor.

*The Allocation of Deceased Donor Kidneys:* The allocation of deceased donors organs is organized using a prioritized waiting list. Patients receive offers when an organ becomes available and may choose to accept or reject it. Each donor’s kidneys are allocated to the highest-priority patients on the waitlist who are willing to accept the organs.

During our sample period, priority was based primarily on waiting time and tissue-type similarity between the patient and donor. Each kidney was first offered to patients with a perfect tissue-type match, then to patients from the local area in which the organs were recovered, then regionally, and finally nationally. Within each priority group, a points system

that emphasized waiting time was used to order patients (see [OPTN, 2014](#), for details). This allocation system evolved over time with incremental changes to enhance efficiency ([Smith et al., 2012](#)).<sup>5</sup>

There are three features of the kidney allocation system that are worth highlighting. First, unlike the assignment systems for some other organs (for example, livers and hearts), the kidney assignment system does not use patient urgency to determine priority. Second, patients who reject an offer remain on the list and may choose to accept the next offer with no penalty in priority for refusing an offer. Third, the design is based on heuristics aided by simulations and compromises in consideration of distributional effects rather than a formal mechanism design approach (see [Stegall et al., 2017](#), for a historical perspective).

## 2.2 Data and Descriptive Analysis

### 2.2.1 Data Sources

This study uses data from the Organ Procurement and Transplantation Network (OPTN). The OPTN data system includes data on all donors, wait-listed candidates, and transplant recipients in the US, submitted by the members of the OPTN. The Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services provides oversight to the activities of the OPTN contractor.

The data include detailed information on patient and donor characteristics, and survival outcomes from the Standard Transplantation Analysis and Research dataset. They also include all offers made by the system and accept/reject decisions from the Potential Transplant Recipient dataset. These data are populated using information gathered during the allocation process, forms submitted by transplant centers from patient follow-ups after a transplant is performed, and patient death dates merged from social security records

We restrict attention to patients who first joined the kidney waiting list between January 1st, 2000 and December 31st, 2010. From this set, we exclude patients who needed multiple organ

---

<sup>5</sup>A revision to the system aimed at improving survival benefits was implemented on December 4, 2014. This system also uses a priority-based waiting list that emphasizes waiting time, geography and patient sensitization. The change gives greater priority to the patients in the top quintile of expected post-transplant survival for the top quintile predicted organ quality.



transplants and those that received a living donor kidney (see Appendix A for a detailed discussion). Correspondingly, we only use data on donor offers and acceptance decisions for our sample of patients.

The survival records are consistently populated until December 31st, 2015, allowing us to track survival outcomes for up to sixteen years from registration for our sample of patients.<sup>6</sup> For patients without death records, we use information from the waitlist for untransplanted patients and from annual post-transplant follow-ups for transplanted patients to construct a censored measure of patient survival.

### 2.2.2 Descriptive Analysis

Table 1: Patient Characteristics

	All Patients		Received Deceased Donor Transplant	
	Mean	S.D.	Mean	S.D.
New Patients per Year	15956		8393	
Panel A: Outcomes				
Died by Year Five (%)	27.4	44.6	9.3	29.1
Survived Five Years (%)	64.2	47.9	86.2	34.4
Censored by Year Five (%)	8.4	27.7	4.4	20.6
Transplanted by Year Five (%)	47.2	49.9	89.7	30.4
Panel B: Characteristics				
Age at Registration	51.4	14.2	48.9	15.2
On Dialysis at Registration (%)	77.3	41.9	75.1	43.2
Diabetic Patient (%)	42.9	49.5	33.4	47.2
BMI at Registration	28.2	5.9	27.6	5.7

Sample includes 175518 patients who registered between 2000 and 2010. Transplant and survival data are available through 12/31/2015. Patients for whom we do not observe death are censored. The observed survival duration is computed based on the date and status of the patient when we last observe her. See A.4 for detailed computation of observed survival. Durations presented in Panel A are time since registration.

*Patients and Donors:* Patients face extreme scarcity, with a significant fraction dying while awaiting a transplant. Panel A of Table 1 shows that an average of 15956 patients registered each year on the kidney waiting list, of which 27.4% die within five years of registering and only 47.2% receive a transplant during this time period. The chances of receiving a transplant decline after the first five years, with only 54% of patients ultimately receiving a

<sup>6</sup>Our data use agreement allows for periodic updates, which we plan to include in future iterations of the paper.

deceased donor kidney. The remaining patients either still await a kidney or leave the list. Panel B shows that patients receiving a transplant are younger and appear to have been in better health at the time of registration. Transplanted patients are less likely to be on dialysis at the time of registration, are less likely to be diabetic, and have a lower body mass index. Thus, observed characteristics induce correlation between probability of receiving a transplant and survival without a transplant.

Table 2: Donor Characteristics

	All Donors		Any Kidney Discarded			
	Mean	S.D.	Yes		No	
			Mean	S.D.	Mean	S.D.
Number of Donors per Year	6181		1169		5012	
Median Number of Offers per Donor	51		482		40	
Average Number of Offers per Donor	543.5	1927.9	1890.5	3684.3	229.3	946.7
Donor Age	39.2	18.4	52.0	16.6	36.2	17.5
Cause of Death -- Head Trauma (%)	39.7	48.9	19.5	39.6	44.5	49.7
Hypertensive Donor (%)	28.6	45.2	55.4	49.7	22.4	41.7
Donor Creatinine	1.2	1.0	1.4	1.1	1.1	0.9
Non-Heart Beating Donor (%)	7.9	26.9	10.4	30.6	7.3	26.0
KDPI	0.5	0.3	0.8	0.2	0.4	0.3

Notes: Sample includes deceased donors offered between 2000 and 2010 to patients in the sample.

Patients exercise choice despite scarcity, often rejecting undesirable organs. Table 2 shows that the number of offers per donor is 543.5, but the median is much lower, at 51. This skewed distribution arises because undesirable kidneys are rejected by many, while desirable kidneys are accepted quickly. Indeed, 18.9% of donors have at least one viable kidney discarded. Organs from these donors were refused by 1890.5 patients on average.

Predictors of organ quality are correlated with number of offers and discards in expected ways. Donors whose kidney(s) was/were discarded are older, less likely to have died from head trauma, more likely to be diabetic or hypertensive, have higher creatinine levels (an indicator of lower kidney function), and more likely to have donated after cardiac death (Table 2). An aggregate of these and other characteristics is the Kidney Donor Profile Index (KDPI), which indicates the fraction of donors with a lower estimated risk of graft failure.

*Survival:* We focus on survival as the primary outcome of interest for several reasons. First,

this outcome is arguably the most important one from the perspective of the patient and also the policy-makers. Predicted LYFT from observational models was explicitly used by the OPTN Kidney Transplantation Committee to evaluate proposed designs. Second, moving an ESRD patient from dialysis to transplantation saves on expensive dialysis treatment. While we do not directly evaluate this component, future research can use our estimates to revisit cost-benefit analyses. Third, this outcome can be measured relatively easily. The other most commonly discussed effect is on quality of life, which is hard to quantify.

Figure 1 shows survival curves for transplanted and untransplanted patients, separated by young and old patients (above/below the median age of 54) and by whether or not the transplanted patient received a kidney from a donor with a discarded kidney. Donors with a discarded kidney are more likely to be undesirable because only one patient accepted the donor’s kidneys. As indicated by the waiting times shown via the vertical dashed lines, the average waiting time for a patient who receives a kidney from a donor without a discard is higher than that for a donor with a discard.


These survival curves show that transplanted patients live significantly longer than patients who do not receive a transplant. Moreover, they are substantially different for young versus old patients and for patients transplanted with a desirable versus undesirable organ. Only about half of the young patients who do not receive a transplant survive more than 7.9 years, but more than half of the young patients who receive a transplant from a donor with desirable organs live past 16 years. These statistics are 5.4 and 11.3 years, respectively, for older patients, indicating that older patients have shorter half-lives both with and without a transplant.<sup>7</sup> For both groups of patients, a transplant from an undesirable organ is associated with half-lives that are shorter by about a year or more.

These observations also point to the potential for choices and assignments to be correlated with survival outcomes. Next, we turn to a model that incorporates these features.

---

<sup>7</sup>We focus on median survival instead of expected life-years because we can track survival for up to sixteen years. This choice is consistent with prior work measuring the life-year benefits from transplantation (see [Wolfe et al., 1999, 2008](#), for example).

Figure 1: Patient Survival



Notes: The figure shows Kaplan-Meier survival curve for young and old patients (above/below the median age of 54) who registered on the waitlist between 2000 and 2010. Survival with transplant is measured as time since registration.

### 3 A Model of Decisions and Outcomes

Our model considers assignment mechanisms in which patients, indexed by  $i$ , receive sequential offers for organs, indexed by  $j$ . Patients must decide to accept or reject each offer. These decisions translate into an assignment, and an outcome is realized. <sup>8</sup>

#### 3.1 Assignment Mechanism and Observed Outcomes

Organs arrive sequentially, their index  $j$  denotes their arrival order. The mechanism orders patients on the waiting list according to an organ-specific priority score that may depend on the time that a patient has waited. Offers are made in this priority order. Acceptance

<sup>8</sup>In our empirical context, patient decisions may be delegated or made jointly with a surgeon. We do not distinguish between these alternatives.

by  $i$  of an offer for organ  $j$  is denoted with  $D_{i,j} = 1$ . Organs are assigned to the highest priority patients that accept an offer. Finally, patients that have been assigned an organ are removed from the list. Other patients may also leave the list.

Consider the set of organs that are feasible for patient  $i$ . Holding fixed the decisions of the other patients, let  $J_i$  be an ordered set of organs offered to patient  $i$  if she refuses all offers made to her and she was registered indefinitely. Because patients may die before assignment, she receives a subset of offers denoted by  $\tilde{J}_i$ . Thus  $\tilde{J}_i = (j \in J_i : Y_{i,0} \geq t_{i,j})$ , where  $t_{i,j}$  is the time between patient  $i$ 's registration and donor  $j$ 's arrival, and  $Y_{i,0}$  is untransplanted survival. Patient  $i$ 's assignment depends both on the feasible set of organs and her decisions. Let  $T_{i,j} = 1$  denote patient  $i$  being assigned organ  $j$ . Note that

$$T_{i,j} = \prod_{j' < j, j' \in \tilde{J}_i} (1 - D_{i,j'}) D_{i,j},$$

where  $D_{i,j} = 1$  if patient  $i$  accepts organ  $j$ . Therefore, each patient  $i$  is assigned to the first organ that she accepts from the set  $\tilde{J}_i$ . We assume that the analyst observes the offer set  $\tilde{J}_i$  and the decisions  $D_{i,j}$  for the offers made  $j \in \tilde{J}_i$ . Observing the choice set and decisions is typical when administrative data from an assignment mechanism is available.

The observed outcome  $Y_i$  depends on whether a patient is assigned and to which organ she is assigned. It is given by

$$Y_i = \sum_{j \in \tilde{J}_i} T_{i,j} Y_{i,j} + \left( 1 - \sum_{j \in \tilde{J}_i} T_{i,j} \right) Y_{i,0},$$

where  $Y_{i,j}$  is the survival outcome of patient  $i$  from being assigned organ  $j$ .

This formulation abstracts away from potential truncation of observed survival for simplicity of notation. In our empirical context, we only observe a censored survival outcome for some patients, allowing us to deduce that  $Y_i > Y_i^C$ , where  $Y_i^C$  is the censoring time. We will account for this censoring, making the standard assumption that the censoring time is independent of the latent duration (see equation 20.22 in [Wooldridge, 2010](#)).

### 3.2 Latent Outcomes and Decisions

There are three key sets of primitives in our model:

**Unassigned Outcome:** The outcome for patient  $i$  if the patient is not assigned any organ is given by

$$Y_{i,0} = g_0(x_i, \nu_{i,0}), \quad (3.1)$$

where  $x_i \in \mathbb{R}^{d_x}$  are patient-specific observables;  $\nu_{i,0} \in \mathbb{R}$  denotes a patient-specific unobservable; and  $Y_{i,0} \in \mathbb{R}$ .

**Assignment Outcome:** The outcome of patient  $i$  from being assigned organ  $j$  is given by

$$Y_{i,j} = g_1(q_j, x_i, \nu_{i,1}, \varepsilon_{i,j,1}), \quad (3.2)$$

where  $x_i \in \mathbb{R}^{d_x}$  is a vector of patient-specific observed characteristics;  $q_j \in \mathbb{R}^{d_q}$  denotes the observed characteristics of organ  $j$ , which we will refer to as organ-types;  $\nu_{i,1} \in \mathbb{R}$  denotes a patient-specific unobservable;  $\varepsilon_{i,j,1} \in \mathbb{R}$  denotes an unobservable that are patient- and organ-specific; and  $Y_{i,j} \in \mathbb{R}$ .

Since  $Y_{i,j}$  and  $Y_{i,0}$  denote survival outcomes in our application, they can be written as arising from survival models with time-varying hazard rates that depend on unobservables. This model allows for rich heterogeneity along observable and unobservable dimensions. It also allows for time to treatment effects since  $x_i$  and  $q_j$  can include the dates on which patient  $i$  and organ  $j$  arrive. Moreover, there are multiple levels of unobserved heterogeneity. Outcomes are heterogeneous across  $i$  due to  $\nu_{i,1}$  and  $\nu_{i,0}$ , and within treatment types (defined by  $q_j$ ) for a given  $i$  because of  $\varepsilon_{i,j,1}$ .

**Decision Equation:** We model the acceptance decision as

$$D_{i,j} = g_D(q_j, x_i, z_i, \nu_{i,D}, \varepsilon_{i,j,D}) \in \{0, 1\} \quad (3.3)$$

where  $D_{i,j} = 1$  denotes accept;  $\nu_{i,D} \in \mathbb{R}$  denotes unobserved selectivity of patient  $i$ ;  $\varepsilon_{i,j,D} \in \mathbb{R}$  is a shock that is specific to the patient and the organ; and  $z_i \in \mathbb{R}^{d_z}$  are

observables that influence the decision of a patient. Without loss of generality, we assume that  $g_D$  is non-increasing in  $v_{i,D}$  and non-decreasing in  $\varepsilon_{i,j,D}$ .

The choice model nests several primitive models of decisions. It is consistent with both myopic decision rules and a dynamic decision process in which patients do not have foresight over future offers, but base their decisions on their beliefs about the distribution of offers. Although we remain agnostic about the micro-foundations, this formulation and our empirical specification nests the optimal stopping problem in [Agarwal et al. \(2021\)](#).<sup>9</sup>

The main difference between  $x_i$  and  $z_i$  is that the latter is excluded from the outcome equations. For example,  $z_i$  could include variables that influence this decision, say through the distribution of future offers, but is unrelated to the benefits of accepting a given organ. This exclusion restriction, combined with Assumption 1(i) below, introduces instruments in the model that we will use in the empirical strategy. The specific instruments  $z_i$  used in our application are discussed in Section 4.

Our data generating process samples a set of patients and a set of organs independently along with their respective characteristics  $(x_i, z_i, \nu_i)$  and  $q_j$ , where  $\nu_i = (\nu_{i,0}, \nu_{i,1}, \nu_{i,D})$ . It then samples the match-specific unobservables  $\varepsilon_{i,j} = (\varepsilon_{i,j,1}, \varepsilon_{i,j,D})$ . We make the following restriction on this process:

**Assumption 1.** (i)  $\varepsilon_i = \{\varepsilon_{i,j}\}_j$  and  $\nu_i$  are mutually independent conditional on  $(x_i, z_i)$  and  $(q_j)_j$ .

(ii) The random vector  $\nu_i$  is distributed independent and identically distributed (i.i.d.) across  $i$ .

(iii) The random vector  $\varepsilon_{i,j}$  is distributed i.i.d. across  $i$  and  $j$ .

The assumption allows for dependence between the components of  $\nu_i$  and the components of  $\varepsilon_{i,j}$ , thereby allowing for  $Y_{i,j}$  and  $Y_{i,0}$  to be correlated with each other and with  $D_{i,j}$ . The

---

<sup>9</sup>In this model, an offer is accepted if the (perceived net present) value from accepting the organ exceeds the option value of waiting. Specifically, let  $g_D = 1$  if  $U_i(q_j, x_i, \varepsilon_{i,j,D}) > V(x_i, \nu_{i,D})$  where  $U(\cdot)$  is the net present value of accepting an offer for  $j$ ,  $V(\cdot)$  is the option value of waiting. [Agarwal et al. \(2021\)](#) estimate this model by first estimating conditional choice probabilities using a probit model where  $g_D = 1 \{f(q_j, x_i, \varepsilon_{i,j,D}; \theta) > 0\}$  using a reduced-form function  $f$  parametrized in terms of  $\theta$ . Their empirical specification is more restrictive than ours as it omits  $\nu_{i,D}$  and  $z_i$ , and does not consider survival effects from transplantation.

independence assumptions imply that patients' outcomes do not depend on other patients' treatment assignment, which implies the stable unit treatment value assumption. The third part of the assumption rules out donor heterogeneity that generates dependence between patients' outcomes and choices. Our empirical model will include donor-level unobserved heterogeneity that is observed by agents but not by the econometrician. The formal results in the main text abstract away from this source of dependence for simplicity of exposition, but we extend our results in appendix C.3 to allow for such heterogeneity.

Our goal is to identify the function  $g_D(\cdot)$  and the marginal distributions of  $Y_{i,j}$  and  $Y_{i,0}$  conditional on the vector  $(x_i, q_j, z_i, \varepsilon_{i,j,D}, \nu_{i,D})$ . The residual uncertainty in the distribution of  $Y_{i,0}$  is only because of patient-specific unobservables  $\nu_{i,0}$ , whereas it is due to both match-specific effects  $\varepsilon_{i,j,1}$  and patient-specific effects  $\nu_{i,1}$  for  $Y_{i,j}$ .<sup>10</sup> Incorporating these sources is necessary for capturing unobserved match-specific drivers of outcomes. Identifying these distributions will also allow us to condition only on a subset of the variables  $(x_i, q_j, z_i, \varepsilon_{i,j,D}, \nu_{i,D})$  depending on the quantities on which counterfactual assignments depend.

The model and Assumption 1 together impose three main restrictions. First, unobserved patient selectivity,  $\nu_{i,D}$  is fixed across all organs and time, implying a fixed ordering of patients on selectivity for all organ types. Second, selectivity and survival outcomes can be correlated through  $\nu_i$ , but we abstract away from time-varying information about survival that is unobserved to the econometrician and also affects decisions. Relaxing these two restrictions is challenging because patients in our setting can accept at most one offer and we observe a single survival outcome (see also Abbring and den Berg, 2003; Unkel et al., 2014). Third, a patient's decision does not depend directly on the specific decisions of other patients for a given organ since  $\nu_i$  and  $\varepsilon_{i,j}$  are independent of  $\nu_{i'}$  and  $\varepsilon_{i',j'}$ .

In addition, we rule out statistical dependence between the subset of organs offered to a patient and her unobservables:

**Assumption 2.** *The sequence of offers  $J_i$  is conditionally independent of  $(\nu_i, \varepsilon_i)$  given  $x_i$ .*

Assumption 2 is satisfied if  $x_i$  controls for a sufficiently rich set of patient characteristics such

---

<sup>10</sup>For example, the first moments of the marginals we identify are  $E[Y_{i,0} | x_i, z_i, \nu_{i,D}] = \int g_0(x_i, \nu) f_{\nu_0 | \nu_D = \nu_{i,D}}(\nu) d\nu$  and  $E[Y_{i,j} | x_i, q_j, z_i, \varepsilon_{i,j,D}, \nu_{i,D}] = \int \int g_1(q_j, x_i, \nu, \varepsilon) f_{\varepsilon_1 | \varepsilon_D = \varepsilon_{i,j,D}}(\varepsilon) f_{\nu_1 | \nu_D = \nu_{i,D}}(\nu) d\nu d\varepsilon$ , where, the distributions of  $\nu_{i,1}$  and  $\nu_{i,0}$  may depend on  $\nu_{i,D}$ , and the distribution of  $\varepsilon_{i,j,1}$  may depend on  $\varepsilon_{i,j,D}$ .



that the remaining variation in potential offers is independent of unobserved determinants of a patient’s outcomes and decisions. The assumption allows for  $J_i$  to depend on the unobservables of other patients  $i'$ . But, because  $J_i$  is excluded from  $i$ ’s potential outcomes and affects assignment, it is an instrument for which organ is assigned to  $i$ . Section 4.1 argues that the assumption is plausible in our empirical setting.

An implication of this assumption is that, patients cannot alter their decisions or their outcomes in response to specific future offers, ruling out foresight over the organs that will be offered in the future. This restriction parallels the “no anticipation” assumption in [Abbring and den Berg \(2003\)](#). Nonetheless, recall that our choice model nests the model in [Agarwal et al. \(2021\)](#) where forward-looking patients strategically refuse offers based on the distribution of future offers.

The sequential nature of choices and treatment assignment in our model resembles that of [Heckman and Navarro \(2007\)](#). There are two main differences. First, outcomes and choices for a patient from different organs of the same type  $q_j$  are heterogeneous in our framework whereas the standard framework uses a finite set of known types. This allows for the realistic possibility that choices and survival outcomes of a patient can vary across two observationally identical donors. Capturing such match-specific effects can be important in other assignment problems with highly heterogeneous agents. Second, our choice shifter  $z_i$  varies at the individual level, not at the individual-treatment level. As we discuss below, we combine this instrument with variation in offers  $J_i$  to identify treatment effects.

### 3.3 Sources of Selection

The model allows for selection into transplantation on three dimensions: untransplanted survival  $Y_{i,0}$ ; average survival across transplants  $\bar{Y}_i = \frac{1}{|J|} \sum_j Y_{i,j}$ ; and match-specific survival  $Y_{i,j} - \bar{Y}_i$ . There are two potential sources of selection: selection due to patient choices and selection due to patient mortality. Selection on these sources creates endogeneity in  $T_{i,j}$  that our framework addresses.

Selection due to choice occurs if choices  $D_{i,j}$  are correlated with survival outcomes  $Y_{i,0}$  or  $Y_{i,j}$ . Choice can induce selection on  $Y_{i,0}$  if, for example, patients with higher expected survival

without a transplant due to unobserved health conditions are more selective. That is, if  $E[Y_{i,0} | \nu_{i,D}, x_i]$  varies with  $\nu_{i,D}$ , where expectations are taken over  $\nu_{i,0}$ . Similarly, choice can induce selection on average transplanted survival,  $\bar{Y}_i$ , if  $E[Y_{i,j} | \nu_{i,D}, x_i, q_j]$  varies with  $\nu_{i,D}$ , where expectations are taken over  $\nu_{i,1}$  and  $\varepsilon_{i,j,1}$ . Choice can also induce selection on match-specific survival  $Y_{i,j} - \bar{Y}_i$  if patients are more likely to accept an organs with high  $Y_{i,j} - \bar{Y}_i$ .

Selection due to mortality occurs because longer-lived patients (high  $Y_{i,0}$ ) are prioritized and have a higher chance of receiving a transplant. Moreover, such selection can also occur due to either time-to-treatment effects or correlation between  $\nu_{i,0}$  and  $\nu_{i,1}$ . Our model also features mortality-induced selection because  $\tilde{J}_i$  only includes organs that arrive prior to  $Y_{i,0}$ .

## 4 Instruments

We now describe and probe the two instruments described above. Section 5 will formally prove identification.

### 4.1 Conditionally Independent Potential Offers

The first instrument exploits randomness in the objects offered to an agent, relying on Assumption 2. We argue that this assumption is plausible in our setting on theoretical and empirical grounds. Our theoretical justification is based on the mechanism used to allocate deceased donor kidneys. Recall that  $J_i$  is the sequence of offers to agent  $i$  if the agent refuses all offers made to her and participated in the mechanism indefinitely. Thus,  $J_i$  depends only on the kidneys that arrive after a patient registers on the waiting list, the decisions of other patients, and determinants of the agent's priority. It does not depend on the decisions made by agent  $i$  or her survival outcome. Our knowledge of the mechanism allows us to include determinants of each patient's priority in  $x_i$  as controls. The remaining variation in  $J_i$  is only due to the stochastic arrival of organs and the decisions of agents other than  $i$ . It is plausible to assume that the arrival of organs is independent of  $(\nu_i, \varepsilon_i)$  because it depends primarily on deaths in the local area. And, the decisions of other agents are independent of  $(\nu_i, \varepsilon_i)$  in a natural equilibrium model of the the waiting list (Agarwal et al., 2021).

We now empirically investigate these assumptions using a specific function of  $J_i$ . To do this, we construct a set of desirable donors that are achievable for patient  $i$  in the two years following the patient's registration. Specifically, we calculate whether patient  $i$  would be placed above the patient in the 10th position on the list for a given donor. A patient is highly likely to receive an offer for an organ from such a donor because only 22.7% of deceased donors are offered to fewer than ten patients. We then calculate the number of donors that would satisfy this criteria for each patient in the two years following the patient's registration date.

The variation in this variable comes from two sources: variation in the organs that arrived in the two years following patient  $i$ 's registration and variation in the patients on the waiting list and their decisions when the organ arrived. Our results use fixed effects to control for differences in a patient's priority, geographical area, and time trends. Therefore, Assumption 2 needs to be satisfied conditional on these controls. The first source of variation is independent of  $i$ 's decisions because specific patients are not considered in organ donation decisions. Indeed, we cannot detect a correlation between patient characteristics and donor characteristics conditional on the controls mentioned above (not reported due to space constraints, available on request). The second source of variation is also plausibly exogenous because, given a particular organ, other patients' decisions should be independent of the selectivity and outcomes of patient  $i$ .<sup>11</sup> Consistent with this claim, Appendix Table D.5 shows that this measure varies substantially across patients and is not significantly correlated with the vast majority of patient characteristics.

Given this exclusion restriction, we establish relevance by showing that potential offers strongly influence whether or not a patient receives a transplant and also the type of organ transplanted. Columns (1) to (4) in Table 3 present estimates from linear probability models to examine the relationship between whether the transplanted organ is high quality (as measured by KDPI) and the number of potential top 10 offers from donors from the corresponding group. Columns (1) and (2) show that the number of offers in both donor categories are positively related to the probability of a transplant, whether or not we con-

---

<sup>11</sup>The only potential effect is if patient  $i$  accepts a kidney that would otherwise have been accepted by another patient who would have been pivotal in determining whether  $i$  would be in the top ten positions for a different donor.

trol for a rich set of patient characteristics. Columns (3) and (4) show that the type of organ transplanted is positively correlated with the number of potential offers from the corresponding type of donor. The F-statistics point to a strong first-stage relationship as they are much higher than the conventional cutoff of 10 used to assess whether an instrument is strong (Stock and Watson, 2012).

Table 3: Top 10 offers: First Stage

	Transplant			
	Any Kidney (1)	Any Kidney (2)	KDPI <= 50% (3)	KDPI > 50% or Missing (4)
log(1 + # Top 10 Offers in 2 Years)				
KDPI <= 50%	0.0322*** (0.00441)	0.0334*** (0.00441)	0.0439*** (0.00306)	-0.0105*** (0.00287)
KDPI > 50% or Missing	0.0303*** (0.00475)	0.0297*** (0.00478)	-0.0128*** (0.00314)	0.0425*** (0.00294)
DSA FE, year FE, and blood type FE	x	x	x	x
Control for Pediatric at Listing	x	x	x	x
CPRA Category Controls	x	x	x	x
Patient Characteristics		x	x	x
F-statistic	93.20	92.23	108.0	130.6
Number of Observations	132715	131105	131105	131105
R-Squared	0.210	0.219	0.171	0.065

Notes: \* p<0.05, \*\* p<0.01, \*\*\* p<0.001. The sample restricts to patients who registered between 2000 and 2008 because the instrument is calculated using offers in the two years post registration. All regressions control for donor service area (DSA) fixed effect, registration year fixed effect, blood type fixed effect, and priority characteristics (an indicator for pediatric at registration, and indicators for CPRA = 0, 20 <= CPRA < 80, CPRA >= 80, and CPRA missing at registration). Patient characteristics include an indicator for female; indicators for age 18-35, 35-50, and 50-65; indicators and linear controls for dialysis time 1-3, 3-5, 5-10, and >10 years; and an indicator for diabetes. Standard errors, clustered by DSA, registration year, and blood type are in parentheses. F-test tests against the null hypothesis that the coefficients on the instruments are zero.

## 4.2 A Choice Shifter: Scarcity

Our second set of instruments are measures of scarcity  $z_i$  that alters an agent's acceptance decisions  $D_{i,j}$  but are excluded from latent outcomes  $Y_{i,j}$ . Patients who expect greater transplant opportunities in the future (lower scarcity) should be less willing to accept a given kidney than otherwise identical patients with fewer opportunities (higher scarcity). These instruments must be correlated with decisions but independent of latent outcomes. Formally,

Assumption 1(i) requires that, conditional on  $x_i$ ,  $(\nu_i, \varepsilon_i)$  is distributed independently of  $z_i$ . We construct two measures of scarcity. The first is a predictor of offers a patient can expect in the future. Fix an offer for donor  $j$  made to patient  $i$  in the calendar quarter  $t$ . Consider the set of offers made in the four quarters before  $t$  to other patients in a comparison group consisting of other patients with the same blood type as  $i$  that registered in the same DSA as  $i$ . We count the subset of offers made to this group of patients when they had the same number of waiting time priority points as patient  $i$  when she received the offer for donor  $j$ . The second is a predictor of donor supply, which is constructed analogously to the first but counts the number of unique donors in this set of offers.

Our analysis will include fixed effects for the DSA, blood-type, and the calendar year of the assignment. Therefore, both instruments exploit variation in scarcity in a patient’s DSA while controlling for secular trends. To assess balance, we investigated whether variations in our measures of scarcity significantly correlate with the characteristics of patients that register in a given year. Reassuringly, Table D.6 in the appendix shows that our scarcity instruments are not significantly correlated with patient characteristics (age, diabetes, female, height, and weight). Our scarcity instruments are also uncorrelated with measures of donor quality (not reported due to space constraints, available on request). The threat to the instrument therefore needs to be a DSA-specific trend in scarcity that is correlates with survival outcomes due to factors beyond patient or donor characteristics.

These instruments are relevant to decisions if they are correlated with beliefs about future offers. This hypothesis is based on the idea that transplant surgeons, who advise patients on decisions, are likely aware of the recent availability of kidneys. Columns (1) to (8) of Table 4 show the results from a linear probability model that regresses a dummy on whether an offer is accepted on the two measures of scarcity and a variety of controls. Both measures of scarcity are negatively correlated with acceptance. Columns (1) and (2) show that the number of donors or number of offers to patients made in the past to the comparison group is negatively correlated with acceptance rates, controlling for patient priority type and fixed effects for DSA, allocation year, and years waited. These magnitudes are robust to adding an extensive set of controls for patient characteristics (columns 3 and 4), and not very sensitive to additional controls for donor and match-specific characteristics (columns 5 through 8).

Table 4: Scarcity Instruments: First Stage

	Acceptance							
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
Log(1 + No. Donors)	-0.0490*** (0.00341)		-0.0479*** (0.00338)		-0.0365*** (0.00324)		-0.0360*** (0.00323)	
Log(1 + No. Offers)		-0.0536*** (0.00185)		-0.0528*** (0.00183)		-0.0439*** (0.00183)		-0.0409*** (0.00182)
Offer Year FE	x	x	x	x	x	x	x	x
Priority Type FE	x	x	x	x	x	x	x	x
DSA FE and blood type FE	x	x	x	x	x	x	x	x
Years Waited at Offer FE	x	x	x	x	x	x	x	x
Patient Characteristics			x	x			x	x
Donor Characteristics					x	x	x	x
Match Characteristics					x	x	x	x
F-statistic	205.8	842.1	200.5	829.8	126.7	575.2	124.2	506.3
Number of Observations	912889	912761	912889	912761	900794	900669	900794	900669
R-Squared	0.166	0.172	0.169	0.174	0.263	0.233	0.265	0.268

Notes: \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ . We use the first 100 offers from each donor between 2000 and 2009, and the dependent variable is acceptance of an offer. All regressions control for DSA fixed effect, blood type fixed effect, and a fixed effect for the number of years waited at the offer, and priority characteristics (an indicator for pediatric at registration, and indicators for  $CPRA = 0$ ,  $20 \leq CPRA < 80$ ,  $CPRA \geq 80$ , and  $CPRA$  missing at registration). Patient characteristics include an indicator for female; indicators for age  $\leq 18$ , 18-35, 35-50, and 50-65; indicators and linear controls for dialysis time 1-3, 3-5, 5-10,  $> 10$  years; and an indicator for diabetes. Donor characteristics include linear age, indicators and linear controls for donor creatinine  $> 0.6$  and  $> 1.8$ , and indicators for diabetes, donation after cardiac death, and expanded criteria donor. Match characteristics include the number of Human Leukocyte Antigen (HLA) mismatches via indicators for 0 HLA mismatch, 0 and 1 DR antigen mismatch, identical blood type, local offers, and linear controls for (+) and (-) age difference, interactions between CPRA indicators and # HLA mismatches, donor age over 40 and pediatric patient, donor age over 55 and patient age 18-35, donor age over 60 and patient age 35-50, and donor age below 60 and patient age 50-65. Standard errors clustered by DSA, offer year, number of years waited at offer, and blood types in parentheses.

A residualized binscatter plot suggests that these relationships are monotonic (not reported due to space constraints, available on request).

## 5 Identification and Estimation

We now show that the instruments introduced in the previous section,  $J_i$  and  $z_i$ , to identify target quantities described in Section 3. Our results condition on the patient type  $x_i$  and omit it for simplicity of notation. We assume the analyst observes the organ types  $q_j$ , the choices  $D_{i,j}$  if  $i$  is offered  $j$ , the set of organs offered to each patient  $\tilde{J}_i$  and the survival outcome for each patient. Our estimator does not require observing the potential offer sequence  $J_i$  as

long as Assumption 2 is satisfied.<sup>12</sup>

The argument proceeds in three parts. First, we use standard arguments to show that variation in the offers received by a patient can be used to recover distributions of the outcomes conditional on certain sequences of choices. Second, we show that the choice model described in equation (3.3) is identified. Third, we combine continuous variation in scarcity with results from the first part to identify the effect of key unobservables on the distribution of outcomes. All proofs are in Appendix C.

### 5.1 Identifying Conditional Expected Outcomes

We start by using variation in offers. Given a realization of  $J_i$ , let  $j(i, n)$  denote the  $n$ -th organ offered to  $i$  and  $q_i = (q_{j(i,1)}, q_{j(i,2)}, \dots, q_{j(i,|q_i|)})$  be the sequence of offer-types offered to  $i$ . Our first result shows that variation in the offer-types can identify a conditional average treatment effect for patients who accept the  $n$ -th offer.<sup>13</sup> Formally, let  $N_i$  be one greater than the number of offers that  $i$  rejects prior to the first acceptance, that is,  $N_i = \min \{n : D_{i,j(i,n)} = 1\}$ .

**Lemma 1.** *Suppose that Assumptions 1 and 2 are satisfied. Fix  $z$  and  $q_i$ . The marginal distributions of  $Y_{i,j(i,n)}$  and  $Y_{i,0}$  conditional on  $N_i = n$ ,  $z_i = z$ ,  $q_i$  and  $Y_{i,0} \geq t_{j(i,n)}$  are identified for all  $n \leq |q_i|$  such that  $P(N_i = n | q_i, z, Y_{i,0} \geq t_{j(i,n)}) > 0$ , and  $(q_{j(i,1)}, \dots, q_{j(i,n)})$  and  $(q_{j(i,1)}, \dots, q_{j(i,n-1)})$  belong to the support of the distribution of offer-types induced by the distribution of  $J_i$ .*

This result uses standard arguments (e.g. Imbens and Angrist, 1994) to identify counterfactual outcomes for patients who would have accepted and be assigned to the  $n$ -th organ offered. Since we directly observe the outcomes  $Y_{i,j(i,n)}$  for patients (facing same scarcity level  $z_i$  and receiving the same offer-type sequence  $q_i$  as  $i$ ) who are assigned to the  $n$ -th organ offered, the challenge is to estimate the unassigned outcomes for these patients. We do this by focusing on the set of unassigned patients who receive either exactly  $n - 1$  or

<sup>12</sup>Nonetheless, we can simulate  $J_i$  in our context using knowledge of the mechanism and data on the offers made for each donor.

<sup>13</sup>Observe that our model and setting do not allow for always takers since a patient cannot be assigned an organ without receiving an offer for one.

exactly  $n$  offers with sequence of types  $(q_{j(i,1)}, \dots, q_{j(i,n-1)})$  and  $(q_{j(i,1)}, \dots, q_{j(i,n)})$ . The former group contains patients with  $N_i > n - 1$  whereas the latter group only contains patients with  $N_i > n$ , with weights given by the observed quantity  $P(N_i = n | q_i, z, Y_{i,0} \geq t_{i,j(i,n)})$ . Monotonicity of the instrument is implied by our model because a patient cannot be assigned a kidney without receiving an offer.

This result allows us to evaluate the life-years gained in the observed assignment because the alternative is that all patients are unassigned. Identifying the distributions above, however, is not sufficient for evaluating their values under a counterfactual assignment of kidneys to patients because the distributions condition on  $N_i = n$ , and are therefore selected on  $\nu_{i,D}$  and  $\varepsilon_{i,j,D}$ . We address this selection problem below.

## 5.2 Identifying the Choice Model

The next step uses the variation in offers identify the function  $g_D(\cdot)$ . To simplify exposition, focus on the case when  $t_{i,j} = 0$  where  $t_{i,j}$  denotes the time difference between donor arrival and patient arrival. In this case,  $\nu_i$  is unselected due to survival while waiting on the list. Therefore, we normalize the marginal distributions of  $\nu_{i,D}$  and  $\varepsilon_{i,j,D}$  to be uniform and assume that  $z$  is supported in the unit interval. These normalizations are without further loss of generality because we have not placed restrictions on the functional form of  $g_D(\cdot)$ . Because our empirical setting involves dynamic assignments, we prove results for the case when  $t_{i,j} > 0$  and differs across  $j$  in appendix C.4.

We need to introduce some notation in order to develop our result. For each value of  $z$  and donor type  $q_j$ , consider two sets of pairs  $(\nu_D, \varepsilon_D)$  such that one set yields  $g_D(q_j, z, \nu_D, \varepsilon_D) = 0$  and the other yields  $g_D(q_j, z, \nu_D, \varepsilon_D) = 1$ . These two sets are separated by the function  $v(\varepsilon_D; q_j, z) = \sup \{ \nu_D \in [0, 1] : g_D(q_j, z, \nu_D, \varepsilon_D) = 1 \}$ , where we adopt the convention that the supremum of the empty set is 0. Since  $\varepsilon_D$  and  $\nu_D$  are uniformly distributed, observe that  $v(\varepsilon_D; q_j, z)$  is equal to the fraction of patients that reject an offer of an organ with type  $q_j$  with probability at most  $\varepsilon_D$  when faced with scarcity  $z$ . Therefore, identifying the function  $v(\varepsilon_D; q_j, z)$  is equivalent to identifying  $g_D(\cdot)$ .

Our next result makes the following assumption on  $v(\cdot; q_j, z)$ :



**Assumption 3.** For each  $q_j$  and  $z$ ,  $v(\cdot; q_j, z)$  is absolutely continuous,  $v(0; q_j, z) = 0$  and  $v(1; q_j, z) = 1$ .

This assumption requires that there are no (interior) values of  $\nu_D$  for which the patient either accepts or rejects all organs of type  $q_j$  when faced with scarcity  $z$ . In other words, there are high (low) enough match-specific shocks  $\varepsilon_D$  that would result in acceptance (rejection) of an offer, where the pivotal value of  $\varepsilon_D$  depends on  $\nu_D$ ,  $q_j$  and  $z$ . This condition would be violated only if acceptance probabilities were degenerate for some  $q_j$ ,  $z$  and  $\nu_D \in (0, 1)$ . With this assumption, we show that variation in offers can be used to identify the function  $g_D(\cdot)$ :

**Lemma 2.** Let  $q_j^n$  be a sequence composed by  $n$  offers of type  $q_j$  with  $t_{i,j} = 0$ , and let  $v_{n-1}(\cdot; q_j, z)$  be the  $(n-1)$ -st order Fourier-Legendre approximation of  $v(\cdot; q_j, z)$ . If Assumptions 1 - 3 are satisfied, and  $q_j^n$  is in the support of the distribution of offer-types induced by  $J_i$ , then  $v_{n-1}(\cdot; q_j, z)$  is identified for each  $z \in (0, 1)$  and  $q_j$ . In particular, if the hypotheses hold for all  $n$ , then  $v(\cdot; q_j, z)$  and therefore  $P(D_{i,j} = 1 | \nu_{i,D} = \nu_D)$  is identified.

The main challenge is that there are two latent reasons that drive a patient's decisions, namely  $\nu_{i,D}$  and  $\varepsilon_{i,j,D}$ . We observe the probability  $P(N_i > k | q_j^n, z)$  for all  $k \leq n$ . Because  $v(\varepsilon_D; q_j, z)$  is the CDF of rejection probability across patients given  $q_j$  and  $z$ , we can write

$$P(N_i > k | q_j^n, z) = \int_0^1 \varepsilon_D^k d v(\varepsilon_D; q_j, z). \quad (5.1)$$

Therefore, the quantity  $P(N_i > k | q_j^n, z)$  is the  $k$ -th moment of a random variable with cumulative distribution function (cdf)  $v(\cdot; q_j, z)$ . Learning the function  $v(\cdot; q_j, z)$  is related to the Hausdorff moment problem. In general, the cdf of a random variable with bounded support is uniquely determined by its infinitely many moments (Theorem 2.3.11 in [Casella and Berger, 2002](#)). Under the absolute continuity assumption we obtain a stronger result: we show that data with finite  $n$  is informative even without variation in the number of offers because  $v(\cdot)$  can be well-approximated by observing decisions from a *given* sequence of offer-types  $q_j^n$ . This follows because the moments described above determine the  $n$ -th order Fourier-Legendre approximation of  $v(\cdot)$ . The partial mean of these approximations converges to the true function  $v(\cdot; q_j, z)$  as  $n$  becomes large.

### 5.3 Identifying Selection on Unobservables

Next, we turn our attention to identifying the components that determine selection on unobservables using an additional regularity assumption:

**Assumption 4.** (i) For each  $z \in (0, 1)$  and  $q_j$ , the derivative  $v'(\cdot; q_j, z) = \frac{\partial}{\partial \varepsilon_D} v(\cdot; q_j, z)$  is a continuous function for  $\varepsilon_D \in (0, 1)$ . (ii) For each  $q_j$ , the functions  $E[Y_{i,0} | \nu_D]$  and  $E[Y_{i,j} | \nu_D, \varepsilon_{i,j,D} \geq \varepsilon_D, q_j]$  are continuous in  $\nu_D$  and  $\varepsilon_D$  for  $(\nu_D, \varepsilon_D) \in (0, 1)^2$ . (iii) The unconditional expectations of  $Y_{i,0}$  and  $Y_{i,j}$  exist.

The first part strengthens absolute continuity of  $v(\varepsilon_D; q_j, z)$ , imposed in Assumption 3, by requiring existence of a continuous derivative. Given the interpretation of  $v(\cdot)$  above, observe that  $v'(\cdot; q_j, z)$  is the density function of the distribution of the probability with which a patient rejects an offer of an organ with type  $q_j$ . The second part imposes weak regularity assumptions on conditional expectations of  $Y_{i,0}$  and  $Y_{i,j}$ , where expectation is taken over  $\nu_{i,0}$  and  $(\nu_{i,1}, \varepsilon_{i,j,1})$  respectively. The third part requires that these conditional expectations are integrable over the random variables  $\nu_{i,D}$  and  $(\nu_{i,D}, \varepsilon_{i,j,D})$  respectively.

Our main result shows identification of the expected values of  $Y_{i,0}$  and  $Y_{i,j}$  given  $\nu_{i,D}$  and  $\varepsilon_{i,j,D}$ . The result also implies identification of the analogous quantities for any bounded transformation  $\psi(\cdot)$  of  $Y_{i,0}$  and  $Y_{i,j}$ , thereby implying identification of their marginal distributions.

**Theorem 1.** *Suppose that Assumption 4 and the hypotheses for Lemma 2 hold for all  $n$ . Then, the quantities  $E[Y_{i,0} | \nu_{i,D} = \nu_D]$  and  $E[Y_{i,j} | \nu_{i,D} = \nu_D, \varepsilon_{i,j,D} \geq \varepsilon_D, q_j]$  are identified for all  $\varepsilon_D \in (0, 1)$  and  $\nu_D \in (0, 1)$  such that there exists  $z$  in the support of its distribution with  $\nu_D = v(\varepsilon_D; q_j, z)$ .*

Thus, the expected value of outcomes conditional on values of selectivity and idiosyncratic preferences is identified. We sketch the argument for  $E[Y_{i,0} | \nu_D]$  since the intuition for identifying  $E[Y_{i,j} | \nu_D, \varepsilon_{i,j,D} \geq \varepsilon_D, q_j]$  is similar in spirit.<sup>14</sup> The proof begins by using results in Lemma 1 to identify the conditional expectations given scarcity  $z$ , offer-types and  $N_i$ . Next,

---

<sup>14</sup>One qualitative difference is that identifying  $E[Y_{i,0} | \nu_D]$  allows us to use variation in either  $z$  or  $\varepsilon_D$  to trace-out  $\nu_D$ , whereas the result for  $E[Y_{i,j} | \nu_D, \varepsilon_{i,j,D} \geq \varepsilon_D, q_j]$  must condition on  $\varepsilon_D$ .

we use the identification results for  $v(\cdot)$  and arguments in Lemma 2 to recover the objects of interest. For example, Lemma 1 implies that  $E[Y_{i,0} \times 1\{T_i = 0\} | q_j^k, z_i]$  is identified from variation in offers. This quantity can be re-written as

$$E[Y_{i,0} \times 1\{T_i = 0\} | q_j^k, z_i] = \int_0^1 E[Y_{i,0} | \nu_D = v(\varepsilon_D; z_i, q_j)] \varepsilon_D^k dv(\varepsilon_D; z_i, q_j). \quad (5.2)$$

If we observe this quantity for all  $k \leq n$ , then we can recover the  $n$ -th order Fourier-Legendre approximation of  $E[Y_{i,0} | \nu_D = v(\varepsilon_D; q_j, z)] v'(\varepsilon_D; q_j, z)$  when viewed as a function of  $\varepsilon_D$ , which converges uniformly to the true function in Cesàro mean (Freud, 1971). Finally, since  $v'(\varepsilon_D; q_j, z) > 0$  and bounded and the function  $v(\varepsilon_D; q_j, z)$  is identified (Lemma 2), we can identify  $E[Y_{i,0} | \nu_D]$  for all  $\nu_D \in (0, 1)$  if we can find values of  $z$  and  $\varepsilon_D$  such that  $v(\varepsilon_D; q_j, z) = \nu_D$ .

This last step resembles strategies in Heckman and Vytlacil (2005); Lewbel (2007); Heckman and Navarro (2007) whereby a continuous instrument is used to “trace-out” the expected values of potential outcomes conditional on an unobservable. The scarcity instrument  $z$  does this by changing the set of  $(\nu_D, \varepsilon_D)$  whose treatment status changes in response to the offer instrument. Two differences are worth noting. First, our scarcity instrument is not treatment-specific because the discrete offer instrument generates variation in treatment assignments (c.f. Heckman and Navarro, 2007; Hull, 2018, for example). Our assumption that  $\nu_{i,D}$  does not vary across  $j$  allows us to use an instrument that varies only across patients  $i$  but is fixed across  $j$ . Second, we do not use “identification at infinity” arguments as values of  $z$  need not push choice probabilities to degenerate values that obviate the selection problem. Specifically,  $E[Y_{i,0} | \nu_{i,D} = \nu_D]$  and  $E[Y_{i,j} | \nu_{i,D} = \nu_D, \varepsilon_{i,j,D} \geq \varepsilon_D]$  are identified as long as we observe values of  $z$  such that  $\nu_D = v(\varepsilon_D; q_j, z)$ . As is common, identification of  $E[Y_{i,0}]$  and  $E[Y_{i,j}]$  will require full support of  $v(\varepsilon_D; q_j, z)$  for fixed  $\varepsilon_D$  and  $q_j$ .

The results in Lemma 2 and Theorem 1 use data from the case when organs arrive at the same time as the patient ( $t_{i,j} = 0$ ). Extending our results to the case when  $t_{i,j} > 0$  and differs across  $j$  introduces two issues. First is the direct effect of time to treatment, which can be captured by including the patient’s registration date and organ’s arrival date in  $x_i$  and  $q_j$ . The second issue, which is the main challenge, is that the distribution of  $\nu_{i,D}$  conditional on

waiting until  $t_{i,j}$  is no longer unselected.

Our extension in Appendix C.4 addresses these issues and implies identification of the marginal distributions and survival hazard functions of  $Y_{i,0}$  and  $Y_{i,j}$  (Theorem 3). As in generalized Roy models more broadly, the joint distribution of outcomes is not identified. Thus, we cannot attribute the effect of waiting time  $t_{i,j}$  on  $Y_{i,j}$  to either time-to-treatment or to correlation between survival outcomes. We ignore this distinction because it is not relevant for evaluating outcomes under counterfactual assignments.

#### 5.4 Estimation

Although our results above show non-parametric identification, directly estimating these quantities is challenging for several reasons. First, we wish to incorporate rich observed and unobserved heterogeneity governing both choices and outcomes. These include patient-specific, donor-specific, match-specific and time-to-treatment effects. Second, we observe only censored versions of our outcome, complicating a non-parametric analysis. Finally, we would like to incorporate correlations between discrete choices and these censored outcomes. To solve these challenges, we employ a Gibbs' sampling technique to estimate a parametrized version of equations (3.1) – (3.3):<sup>15</sup>

$$y_{i,0} = B(Y_{i,0}; \rho_0) = x_i \beta_x + \nu_{i,0} \quad (5.3)$$

$$y_{i,j} = B(Y_{i,j}; \rho_1) = \chi(x_i, q_j) \alpha_{x,q} + \alpha_\eta \eta_j + \nu_{i,1} + \varepsilon_{i,j,1} \quad (5.4)$$

$$D_{i,j} = 1 \{ \chi(x_i, q_j) \gamma_{x,q} + z_i \gamma_z + \eta_j - \nu_{i,D} + \varepsilon_{i,j,D} > 0 \}, \quad (5.5)$$

where  $Y_{i,0}$  is survival since registration without a transplant;  $Y_{i,j}$  is survival since transplantation if patient  $i$  is transplanted organ  $j$ ;  $B(\cdot; \rho)$  denotes a Box-Cox transformation of the argument with parameter  $\rho$  (Box and Cox, 1964);<sup>16</sup>  $\chi(x_i, q_j)$  is a flexible function of patient observables  $x_i$  and organ observables  $q_j$ ;  $\eta_j$  is distributed  $\mathcal{N}(0, \sigma_\eta^2)$  with the parameter  $\sigma_\eta^2$  to

<sup>15</sup>It is common to use functional form restrictions that are stronger than those necessary for identification when estimating a model that involves selection due to choices and several types of treatments (see Geweke et al., 2003; Hull, 2018, for example).

<sup>16</sup>Formally,  $B(Y; \rho) = \frac{Y^\rho - 1}{\rho}$ . In the special case when  $\rho = 0$ ,  $B(Y, \rho) = \log Y$ . We set  $\rho$  by comparing an estimated survival curve using the non-parametric Kaplan-Meier estimator to those implied by assuming that  $B(Y, \rho)$  is normally distributed.

be estimated;  $\varepsilon_{i,j} = (\varepsilon_{i,j,D}, \varepsilon_{i,j,1})'$  is distributed  $\mathcal{N}(0, \Sigma_\varepsilon)$  where  $\Sigma_{\varepsilon,11}$  is normalized to 1; and  $\nu_i$  is a mean-zero multi-variate normal with a distribution induced by the following factor structure, which is without loss of generality:

$$\nu_{i,1} = \delta_{1,D}\nu_{i,D} + \nu_{i,f} \quad (5.6)$$

$$\nu_{i,0} = \delta_{0,D}\nu_{i,D} + \delta_{0,f}\nu_{i,f} + \tilde{\nu}_{i,0}, \quad (5.7)$$

where  $\nu_{i,D}$ ,  $\nu_{i,f}$  and  $\tilde{\nu}_{i,0}$  are independently distributed mean-zero normal random variables with variances to be estimated.

This empirical model maps the patient and kidney types into characteristic space, which reduces the number of parameters. It includes  $\eta_j$ , which represents unobserved heterogeneity in organ quality due to characteristics observed by patients and surgeons but not included in the empirical specifications. We include this term because it may be empirically important. Appendix C.3 shows identification results analogous to theorem 1 in a non-parametric model that allows for donor heterogeneity  $\eta_j$ . The argument leverages the fact that the same donor's organs are offered to multiple patients on the waiting list. The correlation between the decisions of these patients that cannot be explained by donor-level observables provides information about  $\eta_j$ .

This choice of functional form is motivated by several considerations. First, we wish to allow for correlations between  $\nu_{i,0}$ ,  $\nu_{i,1}$ , and  $\nu_{i,D}$  and between  $\varepsilon_{i,j,1}$  and  $\varepsilon_{i,j,D}$ . For example, the factor  $\nu_{i,f}$  captures the component of a patient's unobserved frailty that is not correlated with decisions. Second, decision are binary, suggesting the use of probit choice models. These two considerations direct us to use multivariate normals to model the distributions of  $\nu_i$  and  $\varepsilon_{i,j}$ . Third, the parametrization allows us to handle censored data and also fit the shape of the survival curve. Box-Cox transformations yield a tractable likelihood function while generalizing the functional form (see Spitzer 1982, for example). We hold the Box-Cox transformation parameters  $\rho_0$  and  $\rho_1$  fixed and conduct robustness analysis to alternative choices (see Table D.7).

Directly computing and maximizing the likelihood of this model is difficult because each patient's data involves decisions over many donors as well as (potentially censored) survival

outcomes. Computing this likelihood requires integrating a nonlinear function over a high dimensional space. Instead, we estimate the parameters of the model using a Gibbs’ sampler (McCulloch and Rossi, 1994; Geweke et al., 2003; Gelman et al., 2014). This method generates a sequence of draws of the model’s parameters, collected in  $\theta$ , and the latent variables  $\nu_i$ ,  $\varepsilon_{i,j}$ , and  $\eta_j$  given the parameters from their respective posterior distributions. Our chosen parametrization is amenable to this approach because the latent variables can be partitioned so that each group has a posterior distribution given the draws of the other groups that can be solved in closed form. Details on the method are provided in Appendix B.1. Based on the Bernstein-von-Mises Theorem (see van der Vaart, 2000, Theorem 10.1), we interpret our estimator as equivalent to maximum likelihood.

## 6 Survival and Choice Estimates

Table 5 present estimates for survival without and with a transplant, and the probability of acceptance in panels A, B and C respectively (detailed estimates are available on request). Our specifications contain a rich set of patient and donor covariates to capture medical history and match quality, including characteristics used in the leading models for predicting pre- and post-transplant survival for patients with kidney failure (see Wolfe et al., 2008, for example) as well as determinants of patient priority. Survival estimates show the marginal half-life effects associated with select characteristics. Effects are shown for a one standard deviation increase in a continuous characteristic or a unit change in an indicator.

We present estimates from three different specifications. The first specification only relies on offer randomness and does not employ the scarcity instruments (columns 1). This specification assumes that  $\nu_{i,D}$ ,  $\nu_{i,0}$  and  $\nu_{i,1}$ , and  $\varepsilon_{i,j,D}$  and  $\varepsilon_{i,j,1}$  are mutually independent. The second specification, which is our preferred one, includes the number of past donors as the scarcity instrument (columns 2). To assess robustness, we estimate a third specification with our past offers instrument (columns 3). Table D.7 in the appendix shows robustness of our headline findings to numerous variations.

*Survival:* Proxies for baseline patient health predict survival both with and without a transplant. A patient who is older, diabetic, or on dialysis at registration has a significantly

shorter half-life both with and without a transplant, with effects that are slightly larger effects for post-transplant survival. For example, a diabetic patient's half-life with and without transplant is lower than a non-diabetic patient by 2.99 and 1.36 years respectively.

Measures of donor quality, waiting time, and tissue-type similarity also predict post-transplant survival, but donor characteristics have lower estimated effects as compared to tissue-type matching and patient characteristics. For example, a donor with a history of hypertension results in a lower half-life by 0.34 years, which is much smaller than the effects on patient characteristics described above. Receiving a kidney with a perfect tissue-type match has a large effect on half-life, consistent with a lower likelihood of an immune responses.

*Choice:* Measures of donor quality and match-specific benefits are also positively correlated with acceptance. Patients are significantly more likely to accept kidney offers from younger donors; donors who died of head trauma; donors without a history of hypertension; and donors with whom they have a perfect tissue-type match. Kidneys which have higher unobservable quality,  $\eta_j$ , are also more likely to be accepted, suggesting that decisions respond to information about the organ that is not perfectly captured by the observable characteristics. The last two rows record the scarcity instruments' effects on acceptance. Consistent with the results in Table 4, each instrument has a significant negative effect on the probability of acceptance. Other parameter estimates are similar across the instrumented specifications, suggesting that the choice between these two instruments is unlikely to be an important driver of our results.

A comparison of estimates across the panels indicate that many organ quality measures positively affect both choice and survival. Tissue-type match and donor death by head trauma are both strongly associated with both choice and survival. That said, the association is not perfect: organs from younger donors are more likely to be accepted even though the survival effects are not significant.

These results qualitatively differ from those in [Abdulkadiroglu et al. \(2020\)](#), who find that preferences for schools are not correlated with value-added after controlling from peer characteristics. An important difference in the institutional context is that choices in our setting are advised by doctors who, given their significant experience and expertise, may have more

Table 5: Survival and Choice Estimates

	Panel A: Survival without Transplant			Panel B: Survival with Transplant			Panel C: Acceptance Model		
	(1)	(2)	(3)	(1)	(2)	(3)	(1)	(2)	(3)
<b>Patient Characteristics</b>									
Diabetic	-1.380 (0.030)	-1.361 (0.030)	-1.361 (0.030)	-2.959 (0.099)	-2.980 (0.113)	-2.977 (0.111)	-0.003 (0.000)	-0.005 (0.001)	-0.005 (0.001)
On Dialysis at Registration	-1.019 (0.042)	-1.013 (0.041)	-1.013 (0.041)	-2.384 (0.118)	-2.395 (0.125)	-2.389 (0.123)	0.001 (0.001)	0.003 (0.001)	0.003 (0.001)
Age at Registration	-1.070 (0.025)	-1.060 (0.025)	-1.060 (0.025)	-3.183 (0.118)	-3.192 (0.126)	-3.181 (0.124)	0.002 (0.000)	0.004 (0.001)	0.004 (0.001)
<b>Donor Characteristics</b>									
Age < 18				1.595 (0.906)	1.604 (0.916)	1.647 (0.916)	0.140 (0.008)	0.153 (0.008)	0.154 (0.008)
Age 18-35				-0.267 (0.973)	-0.282 (0.981)	-0.249 (0.980)	0.079 (0.008)	0.098 (0.008)	0.098 (0.008)
Age 50+				3.383 (2.243)	3.381 (2.252)	3.296 (2.241)	-0.060 (0.002)	-0.071 (0.003)	-0.069 (0.003)
Cause of Death - Head Trauma				0.662 (0.313)	0.665 (0.316)	0.691 (0.314)	0.057 (0.006)	0.065 (0.007)	0.064 (0.007)
Expanded Criteria Donor (ECD)				-0.622 (0.184)	-0.623 (0.199)	-0.655 (0.197)	-0.045 (0.002)	-0.045 (0.002)	-0.045 (0.002)
History of Hypertension				-0.340 (0.122)	-0.342 (0.124)	-0.357 (0.123)	-0.025 (0.001)	-0.029 (0.001)	-0.028 (0.001)
Unobservable ( $\eta_j$ )					0.107 (0.183)	0.181 (0.177)	0.000 (0.000)	0.224 (0.002)	0.219 (0.002)
<b>Offer Characteristics</b>									
Perfect Tissue Type Match				2.272 (0.944)	2.269 (0.959)	2.322 (0.954)	0.146 (0.008)	0.143 (0.009)	0.145 (0.009)
Log Waiting Time (Years)				-0.487 (0.062)	-0.543 (0.168)	-0.539 (0.161)	0.010 (0.000)	0.026 (0.001)	0.016 (0.001)
<b>Scarcity</b>									
Log(1+#Past Donors)								-0.010 (0.001)	
Log(1+#Past Offers)									-0.020 (0.001)
<b>Instruments</b>									
	No Instruments	# Past Donors	# Past Offers	No Instruments	# Past Donors	# Past Offers	No Instruments	# Past Donors	# Past Offers

Notes: Select estimates of the marginal effect on the probability of acceptance and half-life. Marginal effects are computed at the median value of observable covariates, integrating over the distribution of all unobservables. All effects are shown for a one standard deviation increase in each continuous covariate and a unit increase in each binary covariate. We generate 250000 draws and burn-in the first 50000 draws. We thin the chain by selecting every 10 draws. All columns control for DSA fixed effects, blood type fixed effects, and registration year fixed effects. Other patient characteristics include dialysis time at registration, BMI at departure, patient serum albumin, and indicators for female, diabetic, CPRA=0, and prior transplant. Donor characteristics include indicators for other causes of death, expanded criteria donor, donation after cardiac death, male, and bins of creatinine levels. Other offer characteristics include indicators for 2 A, 2 B, 2 DR mismatches, not the same blood type but compatible, regional offer, local offer, and interactions between several patient and donor characteristics. Standard errors are in parentheses.



Table 6: Correlation Table

	Panel A: Selectivity ( $\nu_{i,D}$ )		Panel B: Match value ( $\varepsilon_{ij,D}$ )	
	(1)	(2)	(1)	(2)
Probability of Acceptance	-0.039 (0.001)	-0.039 (0.001)	0.068 (0.001)	0.066 (0.001)
Post-Transplant Survival	0.008 (0.138)	-0.025 (0.134)	0.022 (0.258)	0.122 (0.251)
Survival without a Transplant	0.330 (0.060)	0.323 (0.059)		
Instruments	# Past Donors	# Past Offers	# Past Donors	# Past Offers

Notes: Estimated effects of a one standard deviation increase in choice unobservables affects acceptance and survival probabilities. Survival durations are calculated using half-lives. Survival effects from changes in  $\varepsilon_{ij,D}$  are computed using the expected change in  $\varepsilon_{ij,1}$  from a one standard deviation rise in  $\varepsilon_{ij,D}$  from zero, given the estimated covariance between  $\varepsilon_{ij,D}$  and  $\varepsilon_{ij,1}$ . Likewise, survival effects from changes in  $\nu_{i,D}$  are computed using the expected changes in  $\nu_{i,1}$  and  $\nu_{i,0}$  from a one standard deviation increase in  $\nu_{i,D}$  from zero, given the estimated covariances between  $\nu_{i,D}$ ,  $\nu_{i,1}$ , and  $\nu_{i,0}$ . All effects are computed at the median value of observable covariates.

accurate beliefs about survival effects better than parents have about value-added.

*Selection on Unobservables:* Our model measures the correlation between survival and choice induced by unobservable characteristics. Table 6 shows how a one standard deviation increase in  $\nu_{i,D}$  (selectivity) and  $\varepsilon_{i,j,D}$  (match value) affects acceptance and survival. The selectivity effects are measured by computing the changes on  $\nu_{i,0}$  and  $\nu_{i,1}$  induced by their estimated correlation with  $\nu_{i,D}$ . Likewise, the correlation between  $\varepsilon_{i,j,D}$  and  $\varepsilon_{i,j,1}$  yields the effects of match value.

Selective patients typically survive longer without a transplant and benefit less from the typical transplant. A one standard deviation rise in selectivity lowers the probability of acceptance by 3.9 percentage points. This effect is of similar order as that of a kidney from a donor with a history of hypertension. Therefore, there is positive selection into treatment on the patient-specific component of survival benefits.

In contrast to selectivity, patient-donor specific factors do not induce significant selection via choices. While we estimate the covariance between  $\varepsilon_{ij,D}$  and  $\varepsilon_{ij,1}$  to be positive, the effect is not statistically significant.

## 7 Estimated LYFT

### 7.1 Calculating Life Years from Transplant (LYFT)

For each patient-donor pair, we compute the difference between the median survival time with a transplant and median survival time without a transplant, measured from the date of transplant. Specifically, for each pair  $(i, j)$ , we define LYFT conditional on a set of covariates  $I_{i,j} = \{x_i, q_j, D_{ij}, \eta_j, \nu_{i,D}, \nu_{i,f}\}$  as follows:

$$LYFT(I_{i,j}) = M(Y_{i,j} | I_{i,j}, Y_{i,0} \geq t_{i,j}) - M(Y_{i,0} | I_{i,j}, Y_{i,0} \geq t_{i,j}), \quad (7.1)$$

where  $M(Y|X)$  is the median of random variable  $Y$  conditional on  $X$  and  $t_{i,j}$  is the time between patient  $i$ 's registration and the arrival of kidney  $j$ .<sup>17,18</sup> Therefore, this measure accounts for selection on unobservables induced by the mechanism.

### 7.2 Life Years from Transplant in the Mechanism

Table 7 presents the average estimated LYFT over all realized transplants. The first row accounts for patient- and kidney-specific unobservables and the decision to accept. The second row conditions only on patient and donor observables, integrating  $LYFT(I_{i,j})$  over  $D_{ij}, \eta_j, \nu_{i,D}, \nu_{i,f}$ . The average LYFT from our preferred specification is 8.64 years (column 2). Ignoring selection on unobservables yields a lower estimate of 7.94, suggesting positive selection on LYFT into transplantation based on unobservables. The specification that does not use scarcity instruments yields biased estimates, about two-thirds of a year less than our preferred estimate (column 1). This suggests observational methods used in the medical literature may underestimate gains from transplantation.

The second pair of rows report average survival without a transplant, separately, for all patients and the subset of patients who received a transplant. Across specifications, the

---

<sup>17</sup>Some estimates of LYFT place a weight of 0.8 on life years without a functioning kidney to account for the lower quality of life (e.g. Wolfe et al., 2008). This quality-adjustment is arbitrary and is omitted in our specification.

<sup>18</sup>We use a Gibbs' sampler to compute the expectation of  $LYFT(I_{i,j})$  by drawing  $\eta_j, \nu_{i,D}$ , and  $\nu_{i,f}$  from their conditional distributions given observables, decisions, and observed survival outcomes. We fix the parameters at the estimate  $\hat{\theta}$ , generate 200,000 draws, burn-in the first half, and use every 1,000-th draw.

Table 7: Life-Years from Transplant

	(1)	(2)	(3)	(4)
<b>Life Years from Transplant</b>				
Accounting for Unobservables	7.93 (0.28)	8.64 (0.39)	8.63 (0.33)	8.63 (0.33)
Observables Only	7.90 (0.28)	7.94 (0.49)	7.83 (0.47)	7.71 (0.50)
<b>Untransplanted Survival</b>				
All Patients	7.01 (0.14)	6.95 (0.17)	6.95 (0.15)	6.86 (0.18)
Transplanted Patients	7.34 (0.16)	7.21 (0.20)	7.21 (0.18)	7.17 (0.21)
<b>Post-Transplant Survival</b>				
	15.28 (0.28)	15.84 (0.38)	15.84 (0.33)	15.80 (0.29)
<b>Instruments</b>	<b>No Instruments</b>	<b># Past Donors</b>	<b># Past Offers</b>	<b># Future Donors</b>

Notes: Life years from transplant and survival durations presented in the table are calculated using half-lives. Future donors (offers) is defined as the number of donors (offers) in the next 4 quarters (see Table 4 for detailed definition). All columns control for patient, donor, and offer characteristics, which are defined analogously as in Table 5 Panel B and Table 5. Standard errors are in parentheses.

untransplanted survival for patients who are transplanted is higher than for patients who are not. Thus, choices and the mechanism result in selection on untransplanted survival into transplantation.

### 7.3 Selection and LYFT

The selection on LYFT and untransplanted survival reported in Table 7 above can take place along two margins: the patients who are transplanted and the kidneys to which they are matched. We further investigate these sources below.

*Patient Selection:* There are strong complementarities between baseline health and transplantation. Figure 2(a) presents the joint density of (median) untransplanted survival and the average (median) LYFT from all potential donors for each patient, overlaid with a bin-scatter plot. LYFT and untransplanted survival are strongly positively correlated. Patients who are expected to live longer without a transplant also have the largest life-year gains.

When combined with the observation in Table 7 that transplanted patients have higher baseline survival, this complementarily suggests that patients who are transplanted likely





Figure 2: Patient Selection

have higher LYFT due to selection on baseline health. In addition, there may be patient selection into transplantation from choice and from the priorities in the mechanism.

The overall selection into transplantation is presented in Figure 2(b), which shows the distribution of predicted LYFT across all potential transplants. This distribution is shifted to the right for transplanted patients, with an average that is 1.2 years higher. Thus, the mechanism selects patients with larger average LYFT and that some of this selection comes from transplanting patients who are relatively healthy at baseline.

*Patient-Kidney Matching:* The realized allocation also matches patients to kidneys from which they receive greater survival benefits as compared to the average kidney. Figure 3(a) plots the joint distribution of LYFT from the realized donor for a transplanted patient against LYFT from all potential donors. The bincscatter is below the 45-degree line, indicating that the realized transplants generate greater than average LYFT for a patient. This finding that *matches* are selected advantageously complements the finding that the mechanism selects *patients* with higher than average gains from transplantation.

Part of this advantageous matching comes from the correlation of patients' acceptance decisions with LYFT. Figure 3(b) presents bincscatter plots of kidney-patient acceptance proba-



(a) Transplanted Survival from Potential and Realized Donors

(b) LYFT and Choice

Figure 3: Patient-Kidney Matching

bility against LYFT for all potential transplants, showing two features. First, transplanted patients have a higher predicted probability of acceptance than untransplanted patients. Second, the predicted probability of accepting an offer increases in LYFT. As our estimates suggest, patients are more likely to accept kidneys with greater life-year benefits (based on both observable and unobservable characteristics).<sup>19</sup>

In sum, we find that the allocation matches kidneys to patients based on LYFT and that at least some of this selection is induced by choices in the mechanism.

*Patient Selection vs. Rematching:* Figure 3(a) also provides insight into which of these two assignment margins dominates. The heterogeneity in survival across patients swamps the heterogeneity across donors within a patient. In fact, a decomposition of the total variance in LYFT into patient-specific, donor-specific, and match-specific components (the last being the remainder) shows that the patient-specific component contributes to 6.58 years of the standard deviation in LYFT. The donor-specific and match-specific components are much

<sup>19</sup>To verify this point, we regressed the expected value of  $LYFT_{ij}$  conditional on  $\{x_i, q_j, \eta_j, \nu_{i,D}, \nu_{i,f}\}$  on the probability of acceptance given these same covariates, controlling for patient- and donor-specific fixed effects. A one standard deviation increase in the match-specific component of LYFT raises the probability of acceptance by 0.59 percent.

smaller, accounting for 1.04 years and 0.48 years, respectively.

Thus, the potential for increasing life-years by improving the match between patients and donors without changing which patients are transplanted (rematching) is limited. Distributional constraints may therefore limit the potential gains from improved matching. In particular, maximizing life-year gains may mean reallocating transplants away from the most urgent cases towards patients with longer expected survival without a transplant, pointing to a potential trade-off between efficiency and worst-off prioritarianism for the sickest.

## 8 Potential for Further Increasing LYFT

We now evaluate the performance of the mechanism on LYFT and quantify the importance of patient selection versus rematching. We compare the average LYFT achieved by the realized assignment to benchmarks, ranging from a random assignment to one that maximizes LYFT. Extending patients' lives is a *prima facie* objective of the medical profession. But, this objective may raise distributional concerns or conflict with principles of allocation discussed in medical ethics. We highlight these trade-offs by comparing the types of patients who are transplanted under the benchmarks.

We focus on our preferred specification and, to ease computation, we restrict the sample to the set of patients who registered in 2005. Our results are not sensitive to choice of instrument; varying the Box-Cox shape parameters of our specification; omitting donor unobserved heterogeneity  $\eta_j$ ; or including time between organ extraction and transplantation (see Table D.7).

### 8.1 Comparison with Benchmark Assignments

We start with two extremal benchmarks, random assignment and optimal assignment:

**Random assignment** is simulated by successively assigning patients to kidneys at random from the set of feasible kidneys. Feasibility requires that the patient must be biologically compatible and the kidney should arrive between the patient's registration date and a simulated death date without a transplant. The latter is drawn from that patient's predicted survival distribution.

**Optimal assignment** is computed by maximizing the total LYFT from all transplants. This benchmark considers an omniscient planner who knows  $x_i$ ,  $q_j$ ,  $\nu_{i,D}$ ,  $\nu_{i,f}$ ,  $\eta_j$ , each patient’s arrival and untransplanted death dates, and each kidney’s arrival date. The planner computes LYFT conditional on these characteristics and can dictate assignments. Only feasible transplants are allowed and each patient can receive at most one transplant.<sup>20</sup>

The comparison to the random assignment measures the increase in LYFT achieved by the mechanism. Both selecting patients and advantageously matching kidneys to patients drives the difference. To decompose these sources, we evaluate an alternative that allocates kidneys randomly among transplanted patients:

The **random amongst transplanted** assignment is simulated by re-assigning *transplanted* patients to a kidney at random from the set of feasible kidneys.

The increase in LYFT due to the mechanism results from both the mechanism’s priority rules for kidney offers and the choices made by patients on the waiting list. To separate the gains achieved due to the mechanism’s priority structure from the gains from choice, we evaluate a counterfactual assignment with no patient choice.

The **no choice assignment** is computed by assigning each kidney to the patient with the highest priority among untransplanted patients. Offers cannot be rejected by patients.

Comparing the realized assignment to the optimal assignment bounds the maximum theoretical gain in LYFT that could be achieved by any mechanism. As with the comparison of the realized and random assignments, this gain is driven both by selecting patients and matching patients to kidneys. To decompose these sources, we evaluate an alternative that only reassigns kidneys among transplanted patients:

The **optimal rematching** assignment maximizes the total LYFT using the same information set as in the optimal assignment. In addition to the feasibility constraint, a patient in this assignment can be transplanted only if she was transplanted in the data.

Optimal assignment uses information about factors that induce selection,  $\nu_{i,D}$ ,  $\nu_{i,f}$ , and  $\eta_j$ . However, the first two factors may not be observed by the planner and may be hard to elicit

---

<sup>20</sup>Call the  $s$ -th simulated draw for each patient/donor pair  $LYFT_{ij}^s$ . Let  $a_{ij} = 1$  if  $i$  is assigned  $j$  and  $a_{ij} = 0$  otherwise. Let  $c_{ij} = 1$  if  $i$  is feasible for  $j$  and  $c_{ij} = 0$  otherwise. We solve the problem  $\max_a \sum_{i,j} a_{ij} LYFT_{ij}^s$  subject to  $a_{ij}(1 - c_{ij}) = 0$ ,  $\sum_i a_{ij} \leq k_j$ , where  $k_j$  is the number of kidneys available from donor  $j$ , and  $\sum_j a_{ij} \leq 1$ .




Figure 4: LYFT Under Counterfactual Assignments

in a mechanism. Similarly,  $\eta_j$  may be difficult to condition on. These observations motivate a benchmark that uses only observable information:

The **optimal assignment based on observables** is computed by maximizing the total expected LYFT conditional on  $x_i$  and  $q_j$  by assigning patients to a feasible kidney.<sup>21</sup> The solution describes the highest possible LYFT that can be achieved by a planner who can dictate assignments based on this information.

Figure 4 presents the results. The average LYFT for the realized assignment amongst patients who registered in 2005 is 8.78 years. This is analogous to the results in Table 7 above.

The realized assignment achieves a 0.92 year increase in average LYFT over random assignment. Both selecting patients and matching patients to kidneys are important: random amongst transplanted yields an increase of only 4.4 months. The remainder of the gain is due to patient-kidney matching.

Patient choice is a key contributor to the mechanism's gains in LYFT over random assignment. The no choice assignment results in similar LYFT as the random assignment. Thus, if the priority rules we used to dictate assignments, then only 15.8% of the LYFT increase

<sup>21</sup>For tractability, we assume the planner has foresight on when patients arrive and depart and when kidneys arrive. Relaxing foresight would require solving a dynamic assignment problem with uncertainty about the future.



in the realized assignment would be achieved.<sup>22</sup>

Although the mechanism does better than a random assignment, there is significant scope for further increasing LYFT. The average LYFT under the theoretical upper bound given by the optimal assignment is 5.1 years higher than the LYFT achieved in the realized assignment. Bias in estimates based on observational studies would miss the potential for these gains.<sup>23</sup> A significant fraction, 14.4%, of the increase can be achieved by rematching patients and kidneys while keeping the set of transplanted patients fixed. However, consistent with Figure 3(a), most of the improvements in the optimal allocation come from changing the set of patients who are transplanted.

Finally, a planner who can dictate assignments using the observable characteristics could achieve a significant fraction, but not all, of the potential increase. These observables have been either used to determine priority or considered explicitly in proposed reforms. The average LYFT under the optimal assignment based on observables is 10.48 years. Although less than the theoretical maximum, it is about 1.7 years more than the average LYFT achieved by the mechanism. Therefore, in principle, average LYFT could be substantially raised by targeting transplants using observed characteristics rather than choices.

## 8.2 The Planner’s Dilemma

Achieving the increases in LYFT described above would require changing the set of patients who are transplanted. We now show that this change shifts the demographics and health conditions of transplanted patients, creating a potential barrier due to distributional considerations or the desire to prioritize patient urgency.

The LYFT increases, from random assignment to the mechanism and finally to the optimal solutions, require transplanting relatively healthy patients. Table 8 presents the distribution of patient age, health, and untransplanted survival for patients transplanted under the random assignment, the no choice assignment, the actual assignment, and the optimal assignment. Patients transplanted under the realized assignment are healthier than average –

---

<sup>22</sup>We also simulated the no choice assignment using priorities in place after 2014 and found similar results on LYFT.

<sup>23</sup>A proposed assignment based on maximizing LYFT that uses the specification which omits scarcity instruments yields an average of 11.05 years when evaluated using our preferred specification.

Table 8: Characteristics of Transplanted Patients

	All Patients (1)	Random Assignment		No Choice		Realized Assignment		Optimal Assignment	
		Transplanted		Transplanted		Transplanted		Transplanted	
		Patients (2)	LYFT (3)	Patients (4)	LYFT (5)	Patients (6)	LYFT (7)	Patients (8)	LYFT (9)
Age < 18	3.1%	3.2%	14.81	5.9%	13.70	5.4%	14.89	5.4%	18.83
Age 18 - 35	11.6%	12.3%	11.46	11.9%	11.61	13.0%	12.45	16.8%	15.35
Age 36 - 59	54.8%	55.8%	8.07	53.0%	8.17	54.7%	8.86	57.5%	13.70
Age >= 60	30.5%	28.8%	5.20	29.2%	5.11	26.9%	5.61	20.3%	11.68
White	42.0%	43.4%	7.73	47.8%	7.77	46.4%	8.34	40.9%	13.71
Black	32.7%	31.3%	7.67	30.0%	7.90	30.9%	8.72	32.4%	13.67
Hispanic	16.7%	16.5%	8.21	14.8%	8.89	14.5%	9.65	17.5%	14.31
Other	8.6%	8.8%	8.62	7.4%	8.25	8.2%	10.00	9.2%	14.17
Diabetic	41.4%	40.2%	5.94	37.7%	5.80	33.3%	6.51	31.6%	12.14
On Dialysis at Registration	83.0%	82.3%	7.63	82.0%	7.74	80.2%	8.50	80.7%	13.64
0 HLA Mismatches	-	0.0%	8.00	15.5%	8.18	12.5%	8.59	8.1%	15.55
0 DR Mismatches	-	4.2%	8.55	35.6%	8.11	21.9%	8.86	13.1%	14.87
HLA Mismatches	-	4.75	-	3.62	-	3.92	-	3.80	-
Untransplanted Survival	6.68	6.75	-	6.72	-	6.81	-	7.27	-

younger, less likely to be diabetic, less likely to be on dialysis, and have longer untransplanted survival. Similarly, transplanted patients are also healthier under the optimal assignment than under the realized assignment. The optimal assignments also reallocates kidneys towards racial/ethnic minority patients who have higher LYFT on average than white patients. Comparing the realized assignment and the no choice assignment illustrates the role of choice in increasing LYFT. The existing priority rules target transplants between patients and donors with no HLA mismatches. The fraction of zero-mismatch assignments is lower under the realized and optimal assignments as compared to no-choice. Yet, choice also dramatically changes the selection of who is transplanted towards patients with high LYFT by shifting the age distribution towards younger patients and those with longer untransplanted survival. Therefore, while patients benefit from kidneys with a perfect tissue-type match, reassigning kidneys to the right set of patients without perfect tissue-type matches can increase LYFT. These shifts highlight the distributional effects of optimizing LYFT – the realized outcome increases LYFT by selecting younger, healthier patients to transplant. The optimal assignment exacerbates these distributional changes. These results are driven by the strong correlation between survival with and without a transplant, illustrated in Figure 2(b). Thus, in order to maximize LYFT given the scarcity of kidneys available, the planner must transplant

healthier patients and let sicker patients go untransplanted.<sup>24</sup>

This stark trade-off represents a dilemma. Society may have a moral imperative to prioritize sick patients who may soon die, as done in deceased donor liver allocation. But some medical ethicists discard this principle when faced with scarcity, arguing instead for maximizing total survival or treating people equally (random assignment) (see [Persad et al., 2009](#)). Our results suggest that these two principles are in conflict for kidney allocation, with utilitarian principles also raising concerns about discrimination based on patient characteristics such as age and concerns about increased inequality in patient survival.

## 9 Conclusion

An important but understudied goal in designing assignment mechanisms is to produce matches that improve associated outcomes such as patient survival or student achievement. With few exceptions (noted in the introduction), the prior empirical literature focuses on revealed preference measures of welfare. We take a first step towards an empirical analysis that incorporates downstream outcomes by studying the LYFT generated using the pool of deceased donor kidneys. To do this, we show how to use variation generated in an assignment mechanism to estimate and identify a model that jointly considers choices and outcomes.

We find that the waitlist mechanism used to allocate deceased donor kidneys does better than a random allocation but leaves much scope for improvement. The mechanism transplants patients for whom life would be extended longer, as compared to the average patient, and matches them to more suitable than average kidneys. However, average LYFT could be boosted by several years. The potential economic value of realizing these gains is enormous. [Aldy and Viscusi \(2007\)](#) place the value of a statistical life year at \$300,000. At even half this value and ignoring costs savings on dialysis, the potential benefits from 1 more year of life from the approximately 13,000 deceased donor kidneys transplanted each year accrues to almost \$2 billion per year.

Achieving most of these gains will require confronting important distributional considerations

---

<sup>24</sup>Indeed, an assignment that transplants the sickest patients first (as measured by  $Y_{i,0}$ ) results in an LYFT of 5.67 years.

because survival without a transplant is a strong predictor of life-year gains. Therefore, the planner faces a dilemma between transplanting the sick and transplanting those for whom life will be extended the longest.

This work opens several avenues for further research. First, our approach avoids micro-founding the choice model at the cost of evaluating benchmark assignments rather than the equilibria of alternative mechanisms. This leaves counterfactual selection in an equilibrium model to future work. Second, we focus on an aggregate measure of LYFT that abstracts away from distributional or non-utilitarian ethical considerations. Formalizing these considerations and incorporating them into the design problem could yield a valuable tool for policymaking. The underlying trade-offs are particularly central to designing mechanisms when outcomes are the target, and deserve further research in other contexts as well.

## References

- Abbring, Jaap H. and Gerard J. Van den Berg**, “The nonparametric identification of treatment effects in duration models,” 2003.
- Abdulkadiroglu, Atila and Tayfun Sonmez**, “School Choice: A Mechanism Design Approach,” *American Economic Review*, 5 2003, *93*, 729–747.
- , **Joshua D. Angrist, Yusuke Narita, and Parag A. Pathak**, “Research Design Meets Market Design: Using Centralized Assignment for Impact Evaluation,” *Econometrica*, 2017, *85*, 1373–1432.
- , **Parag A Pathak, Jonathan Schellenberg, and Christopher R Walters**, “Do Parents Value School Effectiveness?,” *American Economic Review*, 5 2020, *110*, 1502–39.
- Agarwal, Nikhil and Paulo J. Somaini**, “Revealed Preference Analysis of School Choice Models,” *Annual Review of Economics*, 2020, *12*.
- , **Itai Ashlagi, Eduardo Azevedo, Clayton Featherstone, and Omer Karaduman**, “Market Failure in Kidney Exchange,” *American Economic Review*, 2019, *109*, 4026–70.
- , – , **Michael A. Rees, Paulo Somaini, and Daniel Waldinger**, “Equilibrium Allocations Under Alternative Waitlist Designs: Evidence From Deceased Donor Kidneys,” *Econometrica*, 2021, *89*, 37–76.
- Aldy, J. E. and W. K. Viscusi**, “Age Differences in the Value of Statistical Life: Revealed Preference Evidence,” *Review of Environmental Economics and Policy*, 2007.
- Atkinson, Anthony B.**, “On the measurement of inequality,” *Journal of Economic Theory*, 9 1970, *2*, 244–263.

- Barvinek, Erich, Ivan Daler, and Jan Francu**, “Convergence of sequences of inverse functions,” *Archivum Mathematicum*, 1991, *27*, 201–204.
- Bates, Michael, Michael Dinerstein, Andrew C. Johnston, and Isaac Sorkin**, “Teacher Labor Market Equilibrium and the Distribution of Student Achievement,” 2022.
- Box, G. E. P. and D. R. Cox**, “An Analysis of Transformations,” *Journal of the Royal Statistical Society: Series B (Methodological)*, 1964.
- Casella, G. and R. L. Berger**, “Statistical Inference, Second Edition,” *Duxbury-Thomson Learning*, 2002.
- Cullen, Julie Berry, Brian A. Jacob, and Steven Levitt**, “The Effect of School Choice on Participants: Evidence from Randomized Lotteries,” *Econometrica*, 9 2006, *74*, 1191–1230.
- Danovitch, Gabriel M**, *Handbook of kidney transplantation*, Lippincott Williams & Wilkins, 2009.
- Dickert-Conlin, Stacy, Todd Elder, and Keith Teltser**, “Allocating scarce organs: How a change in supply affects transplant waiting lists and transplant recipients,” *American Economic Journal: Applied Economics*, 10 2019, *11*, 210–239.
- Freud, GÁ©za**, *Orthogonal Polynomials*, Budapest, Pergamon, Oxford, 1971.
- Gelman, Andrew, John B Carlin, Hal S Stern, and Donald B Rubin**, *Bayesian data analysis*, third ed., Chapman & Hall/CRC Boca Raton, FL, USA, 2014.
- Geweke, John, Gautam Gowrisankaran, and Robert J. Town**, “Bayesian Inference for Hospital Quality in a Selection Model,” *Econometrica*, 2003, *71*, 1215–1238.
- Heckman, James J. and Edward Vytlacil**, “Structural equations, treatment effects, and econometric policy evaluation,” *Econometrica*, 5 2005, *73*, 669–738.
- **and Rodrigo Pinto**, “Unordered Monotonicity,” *Econometrica*, 1 2018, *86*, 1–35.
- **and Salvador Navarro**, “Dynamic discrete choice and dynamic treatment effects,” *Journal of Econometrics*, 2 2007, *136*, 341–396.
- Held, Philip J, F McCormick, A Ojo, and John P Roberts**, “A cost-benefit analysis of government compensation of kidney donors,” *American Journal of Transplantation*, 2016, *16*, 877–885.
- Hull, Peter**, “Estimating Hospital Quality with Quasi-Experimental Data,” *Working Paper*, 2018.
- Imbens, Guido W. and Joshua D. Angrist**, “Identification and Estimation of Local Average Treatment Effects,” *Econometrica*, 1994.

- Irwin, F D, A F Bonagura, S W Crawford, and M Foote**, “Kidney paired donation: a payer perspective,” *American Journal of Transplantation*, 2012, 12, 1388–1391.
- Kapor, Adam, Mohit Karnani, and Christopher Neilson**, “Aftermarket Frictions and the Cost of Off-Platform Options in Assignment Mechanisms,” 2020.
- Larroucau, Tomas and Ignacio Rios**, “Dynamic College Admissions and the Determinants of Students’ College Retention,” 2022.
- Lee, Sokbae and Bernard Salanie**, “Identifying Effects of Multivalued Treatments,” *Econometrica*, 2018, 86, 1939–1963.
- Lewbel, Arthur**, “Estimation of average treatment effects with misclassification,” *Econometrica*, 3 2007, 75, 537–551.
- McCulloch, Robert and Peter E Rossi**, “An exact likelihood analysis of the multinomial probit model,” *Journal of Econometrics*, 1994, 64, 207–240.
- OPTN**, “Organ Procurement and Transplantation Network Policies,” 2014.
- Otero, Sebastian, Nano Barahona, and Caue Dobbin**, “Affirmative Action in Centralized College Admission Systems: Evidence from Brazil,” 2021.
- Persad, G., A. Wertheimer, and E.J. Emanuel**, “Principles for allocation of scarce medical interventions,” *Lancet (London, England)*, 2009, 373, 423–431.
- Robinson-Cortes, Alejandro**, “Who Gets Placed Where and Why? An Empirical Framework for Foster Care Placement,” 2019.
- Roth, Alvin E. and Marilda Sotomayor**, *Two-sided matching: A study in game-theoretic modeling and analysis*, Cambridge Univ. Press, Cambridge, MA, 1992.
- , **Tayfun Sonmez, and M. Utku Unver**, “Kidney Exchange,” *The Quarterly Journal of Economics*, 2004, 119, 457 – 488.
- Roy, A. D.**, “Some thoughts on the distribution of earnings,” *Oxford Economic Papers*, 1951.
- Smith, J. M., S. W. Biggins, D. G. Haselby, W. R. Kim, J. Wedd, K. Lamb, B. Thompson, D. L. Segev, S. Gustafson, R. Kandaswamy, P. G. Stock, A. J. Matas, C. J. Samana, E. F. Sleeman, D. Stewart, A. Harper, E. Edwards, J. J. Snyder, B. L. Kasiske, and A. K. Israni**, “Kidney, pancreas and liver allocation and distribution in the United States,” *American Journal of Transplantation*, 12 2012, 12, 3191–3212.
- Spitzer, John J.**, “A Primer on Box-Cox Estimation,” *The Review of Economics and Statistics*, 1982.

- Stegall, Mark D., Peter G. Stock, Kenneth Andreoni, John J. Friedewald, and Alan B. Leichtman**, “Why do we have the kidney allocation system we have today? A history of the 2014 kidney allocation system,” *Human Immunology*, 1 2017, 78, 4–8.
- Stock, James H and Mark W Watson**, *Introduction to Econometrics Third Edition* 2012.
- Teltser, Keith F.**, “Do kidney exchanges improve patient outcomes?,” *American Economic Journal: Economic Policy*, 2019, 11, 427–453.
- Unkel, Steffen, C. Paddy Farrington, Heather J. Whitaker, and Richard Pebody**, “Time varying frailty models and the estimation of heterogeneities in transmission of infectious diseases,” *Journal of the Royal Statistical Society. Series C: Applied Statistics*, 2014, 63.
- USRDS, United States Renal Data System**, *2018 USRDS annual data report: Epidemiology of kidney disease in the United States*, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018.
- van der Vaart, A. W.**, *Asymptotic Statistics*, Cambridge University Press, 2000.
- Villani, Alfonso**, “On Lusin’s condition for the inverse function,” *Rendiconti del Circolo Matematico di Palermo*, 1984, 33, 331–335.
- Waldinger, Daniel**, “Targeting In-Kind Transfers Through Market Design: A Revealed Preference Analysis of Public Housing Allocation,” 2017.
- Watson, Christopher J E, Rachel J Johnson, and Lisa Mumford**, “Overview of the Evolution of the UK Kidney Allocation Schemes,” *Current Transplantation Reports*, 2020, 7, 140–144.
- Wolfe, R. A., K. P. McCullough, D. E. Schaubel, J. D. Kalbfleisch, S. Murray, M. D. Stegall, and A. B. Leichtman**, “Calculating Life Years from Transplant (LYFT): Methods for Kidney and Kidney-Pancreas Candidates,” *American Journal of Transplantation*, 4 2008, 8, 997–1011.
- Wolfe, R.A., V.B. Ashby, E.L. Milford, A.O. Ojo, R.E. Ettenger, and Others**, “Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.,” *New England Journal of Medicine*, 1999, 341, 1725–1730.
- Wooldridge, Jeffrey M**, “Econometric Analysis of Cross Section and Panel Data,” *MIT Press Books*, 2010, 1.

# Online Appendix for “Choices and Outcomes in Assignment Mechanisms”

Nikhil Agarwal, Charles Hodgson, Paulo Somaini.

## A Data Appendix

### A.1 Obtaining Original Data Files

The data reported here have been supplied by UNOS as the contractor for the Organ Procurement and Transplantation Network (OPTN). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the OPTN or the U.S. Government.

We will retain copies of the data until permitted by our Data Use Agreement with the Organ Procurement and Transplantation Network (OPTN). Further, we plan to send OPTN a copy of our replication archive if and when we are required to destroy our dataset. Researchers interested in using our dataset should directly contact OPTN to obtain permission: <https://optn.transplant.hrsa.gov/data/request-data/>. We are happy to provide copies of our data to researchers with permission and a data use agreement with the OPTN.

### A.2 Data Description

Our data on patients, donors, transplants, and offers are based on information submitted to the Organ Procurement and Transplant Network (OPTN) by its members. The main datasets are the Potential Transplant Recipient (PTR) dataset and the Standard Transplantation Analysis and Research (STAR) dataset.

The PTR dataset contains offers made to patients on the deceased donor kidney waitlist that were not automatically rejected based on pre-specified criteria. Information includes identifiers for the donor, patient, and patient history record that generated the offer; the order in which the offers were made; each patient’s acceptance decision; and if the offer was not accepted, a reason of rejection. Each offer record also contains certain characteristics of



the match, including the number of tissue type mismatches.

The STAR dataset contains separate files on deceased donor characteristics, patient histories, patient characteristics and transplant outcomes, and follow-up data, which are collected at six months and then annually, for kidney transplants. The patient and donor characteristics from these datasets are used to estimate our models of acceptance behavior and patient survival. The patient characteristics and transplant outcomes dataset contains patient death information. For patients who received a transplant through the deceased kidney donor waitlist, the follow-up dataset records whether the patient is still alive at the follow-up point. This information allows us to compute a survival duration for each patient. UNOS also provided supplemental information, including the ordering of distinct match runs conducted for the same deceased donor; the transplant centers of donors and patients in our dataset; and dates of birth for pediatric candidates, who joined the waitlist before turning 18 years of age.

The data contain identifiers that allow us to link the offer and acceptance data to patient and donor characteristics. Each deceased donor has a unique identifier. Similarly, each patient registration generates a unique patient waitlist identifier. Because patients may move to different transplant centers or be registered in multiple centers simultaneously, some individual patients have multiple waitlist identifiers. For this study, we focus on the earliest registration of each patient. The follow-up data contain a unique identifier for each transplant, allowing us to connect the follow-up information to each transplanted patient. The patient history file contains a unique patient record identifier corresponding to a particular state of the patient on the waitlist, including the patient's CPRA, activity status, and pre-set screening criteria. Each offer in the PTR dataset contains the identifiers for the donor, the patient registration, and the patient history record that were used in the match run. When appropriate, we de-duplicate offers so that each patient can receive at most one offer from each donor.

### **A.3 Sample Selection**

We consider the first waiting period for patients who were actively waiting for a deceased donor kidney between January 1, 2000 and December 31, 2010. This restriction is to avoid

selection arising from patients that remain on the list at the beginning of the sample period. We omit patients who received a living donor transplant as their first transplant or were cross-registered for other organs simultaneously. The outcomes for these patients are likely very different from patients who receive only a kidney from a deceased donor. Most patients that can receive a living donor receive one within the first year of registration and would prefer such a transplant to a deceased donor transplant. The latter restriction is made to focus on a more homogeneous group of patients.

In addition, we made a number of other more minor adjustments to work with a more cohesive sample of patients. The number of patients that survive each step of the sample selection process is described in Table [A.1](#).

A small minority of patients are simultaneously registered in multiple donor service areas, indicating that multiple listings and moves are not common. Our analysis keeps only one waitlist record from each patient. If the patient received a kidney transplant through the deceased donor waitlist before December 31, 2015, we keep the waitlist record with the earliest transplant date; if the patient remained untransplanted as of December 31, 2015, we keep the waitlist record with the earliest registration date.<sup>25</sup> Next, we exclude a small number of patients who received a prior kidney transplant to focus on survival effects from the first transplant. We also exclude patients removed for administrative reasons. These are patients who were listed on the waitlist by error, who departed because a transplant took place but no transplant was recorded in the STAR dataset, and who could no longer be contacted while waiting on the waitlist. These departure reasons are recorded in the STAR patient and the transplant outcome dataset.

Then, we keep the waitlist records with registration dates between January 1, 2000 and December 31, 2010 because we do not have data on offers prior to 2000. For example, an untransplanted patient active between 2000 and 2010 may not be included in the final sample because said patient's first waitlist registration is before 2000. This step amounts to be one of the largest cuts.

Finally, we exclude patients who received a transplant through non-standard allocations

---

<sup>25</sup>We use transplant data through December 31, 2015 to be consistent with the sample period during which we observe patient survival.

rules. This can occur, for example, if the donor is an armed service member; if the donor specified a particular recipient (directed donation); if there is a medical emergency or expedited placement attempt; if the kidney is not offered due to operational issue. We identify these cases by analyzing the PTR data as a large number of offers will be bypassed with a code indicating one of these reasons. In some cases, there is also text specifying specific circumstances justifying a rejection, which we parse to identify invalid offers in cases where the refusal code does not provide a specific reason.

Table A.1: Sample Selection: Patients

	Number of Patients	Number of Wait List Records
Patient's first waiting period that intersects the period 2000-2010	308,370	372,681
Exclude patients who received living donor transplants in their first waiting period	241,209	295,075
Exclude patients were waiting for other organs in their first waiting period	213,685	244,580
Keep one kidney waitlist record for each patient	213,685	213,685
Patients with multiple waitlist records	32,191	32,191
Patients with single waitlist record	181,494	181,494
Exclude patients who had a previous kidney transplant	212,258	-
Exclude patients with administrative waitlist removal reason	207,316	-
Restrict to patients whose remaining waitlist registration is between 2000 and 2010	178,944	-
Exclude patients who received non-standard kidney allocations	175,518	-

Our sample of deceased kidney donors comes from the intersection of the STAR deceased donor dataset and the PTR dataset. These are deceased donors whose kidneys were allocated between January 1, 2000 and December 31, 2010 to patients on the waitlist. We further exclude donors allocated using non-standard rules and restrict to donors who were offered to patients in the sample.

Table A.2 details the number of donors that survive each filter. The largest cuts come from the last step. This is because the priority for waiting time implies that many offers are only given to patients that registered prior to 2000.

Table A.2: Sample Selection: Donors

	Number of Donors
Deceased donors offered to any kidney waitlist patients between 2000 and 2010	71,738
Exclude deceased donors offered through non-standard kidney allocations	67,993
Restrict to deceased donors offered to patients in the sample	61,453

We consider a sample of offers made between January 1, 2000 and December 31, 2010 that could have resulted in transplants between our patient and donor samples. The PTR dataset includes records of all initial patient contacts and patients skipped due to administrative reasons irrespective of whether an offer was made. This happens mainly for three reasons. First, some patients that were contacted have lower priority than the patients that accepted and were transplanted the kidneys from a donor. In this case, we determine the cutoff point for each donor, and exclude all offers made after the cutoff. Second, some match runs were abandoned due to logistical reasons, and were re-run. We only keep the offers from the last match run for a donor. Third, in some cases, the PTR dataset records administrative or logistical reasons for skipping patients in the offer sequence. This can occur, for example, if the kidney has antigens that would result in an immune response; a patient was bypassed due to logistical reasons; or if the kidney does not meet the patient’s minimum criteria. We also exclude non-responsive offers, for example, because either the surgeon or the patient is unavailable or because the patient is temporarily inactive/unsuitable for transplantation. Finally, we restrict to offers made to the patients in the sample. This step cuts the offer sample by 41% because many offers are made to patients that were not in our sample, for example, to patients that registered prior to 2000. Table A.3 describes how we arrive at the final sample of offers.

Table A.3: Sample Selection: Offers

	Number of Offers
Offers made between 2000 and 2010 from donors in the sample	14,888,539
Exclude non-responsive offers	14,239,214
Restrict to offers made to patients in the sample	8,444,106

#### A.4 Patient Survival

The patient characteristics and transplant outcomes dataset collects patient death dates from the waitlist record and periodically from the social security master file. In a small minority of cases, death dates are inconsistent across multiple waitlist records for a patient, in which case we assume that earlier death dates take precedence over later ones. Transplant dates

and death dates are truncated on December 31, 2015, because death records after this date are inconsistently populated. For patients who received a transplant or died after December 31, 2015, we treat them as untransplanted or alive, respectively, as of December 31, 2015.

Among 175518 patients in the sample, we observe death dates before December 31, 2015 for 80168 of them. Of these, 55476 are untransplanted patients and 24692 are transplanted. Patients from whom we do not observe death are censored. The censoring rules differ for transplanted and untransplanted patients. For transplanted patients, we censor on the date of the second transplant if a second transplant took place before December 31, 2015; on the day after transplant if there is no follow-up information for the patient corresponding to the transplant; on the date when the patient is lost to follow-up if the patient is lost to follow-up prior to December 31, 2015; and on December 31, 2015 if the patient is known to be alive as of December 31, 2015. For untransplanted patients, we censor on December 31, 2015 if the patient is known to be alive as of December 31, 2015; and on the date when the patient exits the waitlist if no death date is available and the exit day is prior to December 31, 2015. Table A.4 presents a break down of censor reasons and their corresponding censor dates for the patient sample. Nearly one half of the patient sample is uncensored, and among censored patients, the vast majority (73%) are censored on December 31, 2015. Since December 31, 2015 is an exogenously determined date, patients censored on the date should be similar to uncensored patients in terms of potential outcomes.

Table A.4: Censor Reason

Censor Reason	Censor Date	# Patients
<b>Transplanted Patients</b>		
Retransplant before Dec 31, 2015	Retransplant date	3,581
No follow-up information	One day after transplant	979
Lost to follow-up before Dec 31, 2015	Date lost to follow up	5,856
Known to be alive as of Dec 31, 2015	December 31, 2015	57,215
<b>Untransplanted Patients</b>		
Known to be alive as of Dec 31, 2015	December 31, 2015	12,370
No death date and depart the waitlist before Dec 31, 2015	Date departing waitlist	15,349

## B Estimation Appendix

### B.1 Gibbs' Sampler

Recall that our model is given by

$$\begin{aligned} y_{i0} &= B(Y_{i0}; \rho_0) = x_i \beta_x + \nu_{i,0} \\ y_{ij} &= B(Y_{ij}; \rho_1) = \chi(x_i, q_j) \alpha_{x,q} + \alpha_\eta \eta_j + \nu_{i,1} + \varepsilon_{ij,1} \\ D_{ij} &= 1 \{y_{ij,D} = \chi(x_i, q_j) \gamma_{x,q} + z_i \gamma_z + \eta_j + \nu_{i,D} + \varepsilon_{ij,D} > 0\}, \end{aligned}$$

where we allow for  $\nu_i = (\nu_{i,D}, \nu_{i,1}, \nu_{i,2}) \sim \mathcal{N}(0, \Sigma_\nu)$  and  $\varepsilon_{ij} = (\varepsilon_{ij,1}, \varepsilon_{ij,D}) \sim \mathcal{N}(0, \Sigma_\varepsilon)$ .

There are several challenges in estimating this model. First, we often observed censored values of  $y_{i0}$  and  $y_{ij}$ . We perform a data augmentation step given the parameters and the censoring point to solve this issue. For  $y_{ij}$ , the data augmentation step is necessary only in cases for which  $T_{ij} = 1$ .

Second,  $D_{ij}$  is a binary variable. As is standard in discrete choice models, we perform a data augmentation step to draw  $y_{ij,D}$  given the observed decisions. This step is necessary for the observed values of  $D_{ij}$ .

Third, the model incorporates rich correlations between the different observations via  $\eta_j$ ,  $\nu_i$  and  $\varepsilon_{ij}$ . In particular, due to these terms, the covariance matrix between  $\{y_{i0}\}_i$ ,  $\{y_{ij}\}_{ij}$  and  $\{y_{ij,D}\}_{ij}$  conditional on the observables and the parameters does not have a simple block-diagonal structure that would allow us to compute simple posterior distributions. To solve this problem, we re-write these variables using a factor structure such that the posterior distribution of the parameters of each equation is conditionally independent of the others given the factors. Specifically, we rewrite  $\nu_i$  as

$$\begin{aligned} \nu_{i,D} &= f_{i,1} \\ \nu_{i,f} &= f_{i,2} \\ \nu_{i,0} &= \beta_{\nu 1} f_{i,1} + \beta_{\nu 2} f_{i,2} + \tilde{\varepsilon}_{i0} \end{aligned}$$

where  $f_{i,1}$ ,  $f_{i,2}$  and  $\varepsilon_{i0}$  are each independently distributed mean-zero normal random variables with variances  $\sigma_1^2$ ,  $\sigma_2^2$  and  $\sigma_{\varepsilon,0}^2$ . This structure places no restrictions on the covariance matrix  $\Sigma_\nu$ . Similarly, we write  $\varepsilon_{ij}$  as

$$\begin{aligned}\varepsilon_{ij,1} &= \alpha_\varepsilon f_{ij,3} + \tilde{\varepsilon}_{ij,1} \\ \varepsilon_{ij,D} &= f_{ij,3} + \tilde{\varepsilon}_{ij,D}\end{aligned}$$

where  $f_{ij,3}$ ,  $\tilde{\varepsilon}_{ij,1}$  and  $\tilde{\varepsilon}_{ij,D}$  are independently distributed mean-zero normal random variables with variances  $\sigma_3^2$ ,  $\sigma_{\tilde{\varepsilon},1}^2$  and  $\sigma_{\tilde{\varepsilon},D}^2$ . We normalize the variances  $\sigma_3^2$ , and  $\sigma_{\tilde{\varepsilon},D}^2$  to 1. Finally, set

$$\eta_j = f_{j,4}$$

with variance  $\sigma_4^2$ . The main difference between  $f$  and  $\tilde{\varepsilon}$  is that it is sufficient to condition on the former in order to render the models above as conditionally independent.

Therefore, the parameters we are interested estimating in are the co-efficients in each equation,  $\beta = (\beta_x, \beta_{\nu 1}, \beta_{\nu 2})$ ,  $\alpha = (\alpha_{x,q}, \alpha_\eta, \alpha_{\nu 1}, \alpha_\varepsilon)$ ,  $\gamma = (\gamma_{x,q}, \gamma_z)$ , and the variances  $\sigma_{\tilde{\varepsilon},0}^2 = V[\tilde{\varepsilon}_{i0}]$ ,  $\sigma_{\tilde{\varepsilon},1}^2 = V[\tilde{\varepsilon}_{ij,1}]$  and  $\sigma_l^2 = V[f_l]$  where  $l \in \{1, 2, 4\}$  is the  $l$ -th factor.

For simplicity of notation, we will collect the coefficients in the vector  $\theta$  and the standard deviations in the vector  $\sigma$ , with  $\sigma_\varepsilon$  and  $\sigma_f$  denoting the sub-vectors for  $\tilde{\varepsilon}$  and  $f$  respectively. And, with some abuse of notation, we collect  $y_{i0}$ ,  $y_{ij}$  and  $y_{ij,D}$  for all  $i$  and  $j$  in  $y$ .

Following standard practice, we assume diffuse conjugate and independent priors for each of these parameters. Specifically, we model the priors  $\alpha$ ,  $\beta$  and  $\gamma$  using a mean-zero independent normal distribution with variances equal to 1000 and the prior for the variances  $\sigma_{\tilde{\varepsilon},0}^2$ ,  $\sigma_{\tilde{\varepsilon},1}^2$  and  $\sigma_l^2$  using independent inverse-Wishart distributions with parameters  $(3, 3)$ . These priors are diffuse; thus, they have a negligible impact on our estimates.

The Gibbs' sampler starts with an initial draw  $y^0$ ,  $\theta^0$ ,  $\sigma^0$  and  $f^0$  and generates a chain of length  $K$  by iterating through the following steps for each  $k \in \{0, \dots, K-1\}$ :

1. **Data Augmentation:** Sample  $y_{i0}^{k+1}$ ,  $y_{ij}^{k+1}$  for censored observations and  $y_{ij,D}^{k+1}$  for observed decisions given  $\theta^k$ ,  $\sigma^k$  and  $f^k$  from truncated normal distributions.

2. **Sample Coefficients:** Sample  $\theta^{k+1}$  given  $y^{k+1}$ ,  $f^k$ , the standard deviations  $\sigma^k$  and the prior distribution from a multi-variate normal distribution.
3. **Sample Variances:** Sample  $\sigma_{\bar{\varepsilon},0}^{2,k+1}$  and  $\sigma_{\bar{\varepsilon},1}^{2,k+1}$  given  $y^{k+1}$ ,  $f^k$ , the parameters  $\theta^{k+1}$  and the prior distribution from a inverse-Wishart distribution.
4. **Sample Factors:** For each  $l \in \{1, 2, 3, 4\}$ , sample  $f_{\cdot,l}^{k+1}$  given  $y^{k+1}$ , the parameters  $\theta^{k+1}$ ,  $\sigma_{\bar{\varepsilon}}^{k+1}$ ,  $\sigma_f^k$ , and the remaining factors  $f_{\cdot,1}^{k+1}, \dots, f_{l-1}^{k+1}$  and  $f_{\cdot,l+1}^k, \dots, f_4^k$ .
5. **Sample Factor Variances:** Sample  $\sigma_l^{2,k+1}$  for  $l \in \{1, 2, 4\}$  given  $f^{k+1}$  and the prior distribution from an inverse-Wishart distribution.

We draw a chain of length  $K = 200,000$  and burn 50,000 draws to allow the chain to convergence. We only keep one every 10 draws to save some computation time and reduce the autocorrelation in the resulting chain. To diagnose the potential for non-convergence, we visually inspect the chains and, as recommended in [Gelman et al. \(2014\)](#), we also ensure that the potential scale reduction factor is below 1.1 for each of the parameters. The distributions in each step can be solved for in closed-form as detailed below:

1. Conditional distributions for  $y_{i0}$ ,  $y_{ij}$  and  $y_{ij,D}$  given  $\theta$ ,  $f$  and  $\sigma$ :
  - (a) For each  $i, j$  pair with  $D_{ij}$  is observed, the distribution of  $y_{ij,D}$  conditional on  $\gamma$ ,  $f$  and  $D_{ij}$  is a truncated normal with mean  $E[g_{ij,D}|\gamma, f_{ij}]$  and unit standard deviation. The distribution is truncated below at 0 if  $D_{ij} = 1$  and above at 0 otherwise.
  - (b) For each  $i$  such that  $y_{i0}$  is censored, the distribution of  $y_{i0}$  conditional on  $\beta$  and  $f$  is a one-sided truncated normal with mean  $E[y_{i0}|\beta, f_{i1}, f_{i2}]$  and standard deviation  $\sigma_{\bar{\varepsilon},0}$ . The distribution of  $y_{i0}$  is truncated below at the censoring duration.
  - (c) For each observed transplant with  $y_{ij}$  censored, the distribution of  $y_{ij}$  conditional on  $\alpha^k$ ,  $f^k$  is a one-sided truncated normal with mean  $E[y_{ij}|\alpha, f]$  and standard deviation  $\sigma_{\bar{\varepsilon},1}$ . The distribution of  $y_{ij}$  is truncated below at the censoring duration.
2. Posterior distributions of the co-efficients  $\alpha$ ,  $\beta$  and  $\gamma$  given  $y$ ,  $f$ ,  $\sigma$  and the priors. Since  $y_{i0}$ ,  $y_{ij}$  and  $y_{ij,D}$  are mutually independent conditional on  $f$ , the parameters  $\alpha$ ,



$\beta$  and  $\gamma$  are each co-efficients in a linear regression model with normally distributed errors. Therefore, the posterior distributions of each of these terms is given by a multivariate normal distribution with closed-form means and variances ([Gelman et al., 2014](#), Chapter 14.2).

3. Posterior distributions of  $\sigma_{\tilde{\varepsilon},0}^2$  and  $\sigma_{\tilde{\varepsilon},1}^2$  given  $y$ ,  $f$ ,  $\sigma$  and the priors. As above,  $y_{i0}$ ,  $y_{ij}$  are mutually independent conditional on  $f$ . Therefore, the distributions of  $\sigma_{\tilde{\varepsilon},0}^2$  and  $\sigma_{\tilde{\varepsilon},1}^2$  are inverse-Wishart with parameters given in Chapter 14.2 of [Gelman et al. \(2014\)](#).
4. Posterior distributions of  $f$  given  $y$ ,  $\theta$  and  $\sigma$ :

- (a) The distribution of  $f_{i,1}$  conditions on the residual

$$f_{i,1} + \frac{1}{\beta_{\nu 1}} \tilde{\varepsilon}_{i0} = \frac{1}{\beta_{\nu 1}} (y_{i0} - (x_i \beta_x + \beta_{\nu 2} f_{i,2}))$$

and  $\sigma_1$  throughout; on the residual

$$f_{i,1} + \tilde{\varepsilon}_{ij,D} = y_{ij,D} - (\chi(x_i, q_j) \gamma_{x,q} + z_i \gamma_z + \eta_j + f_{ij,3})$$

for all  $j$  such that  $D_{ij}$  is observed; and on the residual

$$f_{i,1} + \frac{1}{\alpha_{\nu 1}} \tilde{\varepsilon}_{ij,1} = \frac{1}{\alpha_{\nu 1}} (y_{ij} - (\chi(x_i, q_j) \alpha_{x,q} + \alpha_{\eta} \eta_j + f_{i,2} + \alpha_{\varepsilon} f_{ij,3}))$$

if  $T_{ij} = 1$ . These residuals have prior mean zero and variances  $\sigma_1^2 + \frac{\sigma_{\tilde{\varepsilon},0}^2}{\beta_{\nu 1}^2}$ ,  $\sigma_1^2 + \sigma_{\tilde{\varepsilon},1}^2$  and  $\sigma_1^2 + \frac{\sigma_{\tilde{\varepsilon},1}^2}{\alpha_{\nu 1}^2}$  respectively. The posterior mean of  $f_{i,1}$  is the precision-weighted average of the residuals corresponding to  $i$ , and the posterior variance is the inverse of the sum of  $\sigma_1^{-2}$  and the precisions of each residual.

- (b) The distribution of  $f_{i,2}$  is analogous, where we condition on  $\sigma_2$  and the residual

$$\frac{1}{\beta_{\nu 2}} (y_{i0} - (x_i \beta_x + \beta_{\nu 1} f_{i,1}))$$

throughout; and on the residual  $y_{ij} - (\chi(x_i, q_j) \alpha_{x,q} + \alpha_{\eta} \eta_j + \alpha_{\nu 1} f_{i,1})$  if  $T_{ij} = 1$ .

- (c) The distribution of  $f_{i,j,3}$  is analogous, where we condition on  $\alpha_\varepsilon$  throughout; on  $y_{ij,D} - (\chi(x_i, q_j) \gamma_{x,q} + z_i \gamma_z + \eta_j + f_{i,1})$  for all  $j$  such that  $D_{ij}$  is observed; and on  $\frac{1}{\alpha_\varepsilon} (y_{ij} - (\chi(x_i, q_j) \alpha_{x,q} + \alpha_\eta \eta_j + f_{i,2}))$  if  $T_{ij} = 1$ . Note that  $\sigma_3$  is normalized to 1.
- (d) The distribution of  $f_{i,j,4}$  is analogous, where we condition on  $\sigma_4$  throughout; on  $y_{ij,D} - (\chi(x_i, q_j) \gamma_{x,q} + z_i \gamma_z + f_{i,1} + f_{i,j,3})$  for all  $i$  such that  $D_{ij}$  is observed; and on  $\frac{1}{\alpha_\eta} (y_{ij} - \chi(x_i, q_j) \alpha_{x,q} + f_{i,2} + \alpha_\varepsilon f_{i,j,3})$  if  $T_{ij} = 1$ .
5. The variances  $\sigma_l^2$  for  $l \in \{1, 2, 4\}$  follow an inverse-Wishart distributions given the prior and respectively,  $\{f_{i,1}\}$ ,  $\{f_{i,2}\}$  and  $\{f_{i,4}\}$ .

## C Theoretical Appendix

### C.1 Notation and Preliminary Results

Let  $\Gamma_l(x)$ ,  $l = 0, 1, \dots$  be the orthonormal shifted Legendre polynomials on  $[0, 1]$ . The first three polynomials are  $\Gamma_0(y) = 1$ ,  $\Gamma_1(y) = \sqrt{3}(2y - 1)$ , and  $\Gamma_2(x) = \sqrt{5}(6x^2 - 6x - 1)$ . In general,  $\Gamma_l(x) = \sum_{k=0}^l \gamma_{l,k} x^k$  for known constants  $\gamma_{l,k}$ . The Fourier-Legendre approximation of degree  $m$  of a function  $g$  defined on  $[0, 1]$  evaluated at  $x$  is denoted by  $s_m(g; x)$  and is given by:

$$s_m(g; x) = \sum_{l=0}^m \Gamma_l(x) \int_0^1 g(y) \Gamma_l(y) dy.$$

Because the Legendre polynomials are orthonormal, we can refer to terms  $\int_0^1 g(y) \Gamma_l(y) dy$  as the  $l$ -th coefficient of the Fourier-Legendre approximation of  $g$  without explicitly referring to the degree of the approximation. For the rest of this subsection,  $F(\cdot)$  is a cumulative distribution function for a random variable with support on  $[0, 1]$ , i.e,  $F(1) = 1$ .

**Lemma 3.** *If  $g(x)$  a continuous function for all  $x \in [a, b] \subset (0, 1)$ , the partial average  $S_n(g; x) = \frac{1}{n} \sum_{m=0}^{n-1} s_m(g; x)$  converges to  $g(x)$  uniformly in  $[a, b]$ .*

*Proof.* The result is a corollary of Theorem IV.3.2 in [Freud \(1971\)](#). To apply this result, we will use the cumulative distribution function of the uniform distribution on  $[0, 1]$  as the function  $\alpha(x)$  in the statement of the theorem, and the Legendre polynomials  $\Gamma_n(x)$  as

$p_n(d\alpha; x)$  for  $n = 0, 1, 2, \dots$ . It is straightforward to check that this sequence of polynomials satisfies the conditions in Theorem I.1.2 of [Freud \(1971\)](#) for the chosen  $\alpha(x)$ . Moreover, this sequence is unique as noted in the remark below Theorem I.1.2 in [Freud \(1971\)](#).

Therefore, it remains to show that  $p_n(d\alpha; x)$  satisfies requirement (3.2) in Chapter IV of [Freud \(1971\)](#). The author notes that Theorem III.3.3 implies that it is sufficient to show that for every pair  $x_2$  and  $x_1$  in a neighborhood of  $x_0 \in [a, b] \subset (0, 1)$ ,  $\frac{\alpha(x_2) - \alpha(x_1)}{x_2 - x_1}$  is bounded below by some positive constant. This the case because for our chosen  $\alpha(x)$ , the expression is equal to 1 for every  $x_1, x_2 \in (0, 1)$ .

Finally,  $s_m(g; x)$ , as defined in equation IV(1.3) of [Freud \(1971\)](#) is the  $m$ -th order Fourier-Legendre approximation of  $g$ . Therefore, by Theorem IV.3.2 in [Freud \(1971\)](#),  $S_n(g; x)$  converges to  $g(x)$  uniformly in  $[a, b] \subset (0, 1)$ .  $\square$

**Lemma 4.** *The  $l$ -th coefficient of the Fourier-Legendre approximation of the function  $f$  is a known linear function of  $\phi_k = \int_0^1 x^k f(x) dx$  for  $k = 0, 1, \dots, l$ . The partial average  $\frac{1}{n} \sum_{m=0}^{n-1} s_m(f, x)$  converges uniformly to  $f(\cdot)$  over any interval  $[a, b] \subset (0, 1)$  on which the function  $f(\cdot)$  is continuous.*

*Proof.* The  $l$ -th coefficient of the Fourier-Legendre approximation of degree of  $f$  is

$$\int_0^1 \Gamma_l(x) f(x) dx = \int_0^1 \sum_{k=0}^l \gamma_{l,k} x^k f(x) dx = \sum_{k=0}^l \gamma_{l,k} \int_0^1 x^k f(x) dx = \sum_{k=0}^l \gamma_{l,k} \phi_k.$$

The partial average  $\frac{1}{n} \sum_{m=0}^{n-1} s_m(f, x)$  converges uniformly to  $f(\cdot)$  over any interval  $[a, b] \subset (0, 1)$  on which the function  $f(\cdot)$  is continuous by [Lemma 3](#).  $\square$

**Lemma 5.** *Let  $\zeta_k = \int_0^1 x^k dF(x)$  be the  $k$ -th moment of  $F(\cdot)$  for  $k = 0, 1, \dots$ . If  $F(\cdot)$  is absolutely continuous, (i) the  $l$ -th coefficient of the Fourier-Legendre approximation of  $F$  is a linear function of the moments  $\zeta_1, \dots, \zeta_{l+1}$ ; (ii) the partial average  $\frac{1}{n} \sum_{m=0}^{n-1} s_m(F, x)$  converges uniformly to  $F(\cdot)$  over any interval  $[a, b] \subset (0, 1)$ .*

*Proof.* The  $l$ -th coefficient of Fourier-Legendre approximation of  $F(x)$  is given by

$$\begin{aligned} c_l &= \int_0^1 \Gamma_l(x) F(x) dx \\ &= \left( \int_0^1 \Gamma_l(x) dx - \int_0^1 \int_0^x \Gamma_l(y) dy dF(x) \right), \end{aligned}$$

where the second equality follows from integration by parts, which holds by absolute continuity of  $F(\cdot)$ , and the fact that  $F(1) = 1$ . For  $l = 0$ ,  $\Gamma_0(y) = 1$  and

$$c_0 = 1 - \int_0^1 x dF(x) = 1 - \zeta_1. \quad (\text{C.1})$$

For  $l > 0$ ,  $\int_0^1 \Gamma_l(x) dx = \int_0^1 \Gamma_l(x) \Gamma_0(x) dx = 0$ . Therefore,

$$\begin{aligned} c_l &= - \int_0^1 \int_0^x \Gamma_l(y) dy dF(x) = - \int_0^1 \sum_{k=0}^l \gamma_{l,k} \frac{1}{k+1} x^{k+1} dF(x) \\ &= - \sum_{k=0}^l \gamma_{l,k} \frac{1}{k+1} \zeta_{k+1}. \end{aligned} \quad (\text{C.2})$$

Equations (C.1) and (C.2) imply that all  $c_l$  for  $l < n$  can be written in terms of the moments  $\zeta_1, \dots, \zeta_{l+1}$ . This proves part (i). Part (ii) follows from Lemma 3 because  $[a, b] \subset (0, 1)$  and  $F(\cdot)$  is continuous.  $\square$

**Lemma 6.** *Suppose (i)  $F(\cdot)$  is absolutely continuous with a density  $f(\cdot)$  that is continuous in an interval  $[a, b] \subset (0, 1)$ , (ii) functions  $g(\cdot), \tilde{g}(\cdot)$  are integrable on the unit interval and continuous in the interval  $[F(a), F(b)]$ , and (iii)  $g(y) \neq \tilde{g}(y)$  for some  $y \in (F(a), F(b))$ , then there exists a finite integer  $k$  such that  $\int_0^1 g(F(x)) x^k dF(x) \neq \int_0^1 \tilde{g}(F(x)) x^k dF(x)$ . Thus, if  $f(\cdot)$  and the scalars  $\int_0^1 g(F(x)) x^k dF(x)$  for  $k = 0, 1, 2, \dots$  are identified, then  $g(\cdot)$  is identified in the interval  $(F(a), F(b))$ .*

*Proof.* Consider a pair of real-valued continuous functions  $g(\cdot)$  and  $\tilde{g}(\cdot)$  defined on the closed unit interval such that  $g(y) \neq \tilde{g}(y)$  for some  $y \in (F(a), F(b))$ . If  $F(a) = F(b)$ , the conclusion is vacuously true. If  $F(a) < F(b)$ , continuity of  $g(\cdot)$  implies that  $g(\tilde{y}) \neq \tilde{g}(\tilde{y})$  for all  $\tilde{y}$  in an open neighbourhood  $B_\delta(y)$  for some  $\delta > 0$ . Take  $\underline{y}, \bar{y} \in B_\delta(y) \cap (F(a), F(b))$  with  $\underline{y} < \bar{y}$ . Since  $F(\cdot)$  is absolutely continuous,  $F^{-1}(\underline{y}) < F^{-1}(\bar{y})$ , where  $F^{-1}(\cdot)$  denotes the

quantile function of  $F(\cdot)$ . By the mean-value theorem, there exist  $x^* \in (F^{-1}(\underline{y}), F^{-1}(\bar{y}))$  such that  $f(x^*) > 0$ ; thus,

$$\Delta \equiv |g(F(x^*))f(x^*) - \tilde{g}(F(x^*))f(x^*)| > 0.$$

Let  $u(x) = g(F(x))f(x)$  and  $\tilde{u}(x) = \tilde{g}(F(x))f(x)$ . The function  $u(x)$  is continuous in  $[a, b]$  because it is the product of continuous functions. Lemma 3 implies that  $\frac{1}{n} \sum_{m=0}^{n-1} s_m(u, x)$  and  $\frac{1}{n} \sum_{m=0}^{n-1} s_m(\tilde{u}, x)$  converge respectively to  $u(x)$  and  $\tilde{u}(x)$  uniformly in  $[a, b]$ . Thus, there exist an  $n$  such that for all  $x \in [a, b]$ ,  $\left| \frac{1}{n} \sum_{m=0}^{n-1} s_m(u, x) - u(x) \right| < \frac{\Delta}{3}$  and  $\left| \frac{1}{n} \sum_{m=0}^{n-1} s_m(\tilde{u}, x) - \tilde{u}(x) \right| < \frac{\Delta}{3}$ . By the triangle inequality,  $\left| \frac{1}{n} \sum_{m=0}^{n-1} (s_m(\tilde{u}, x^*) - s_m(u, x^*)) \right| > \frac{\Delta}{3}$  which implies that  $|s_m(\tilde{u}, x^*) - s_m(u, x^*)| > \frac{\Delta}{3}$  for some  $m < n$ . Thus, the two Fourier-Legendre approximations  $s_m(\tilde{u}, \cdot)$  and  $s_m(u, \cdot)$  have a different  $l$ -th coefficient for some  $l \leq m$ . Define  $\phi_k = \int_0^1 g(F(x))x^k dF(x)$  and  $\tilde{\phi}_k = \int_0^1 \tilde{g}(F(x))x^k dF(x)$ . By Lemma 4,  $\phi_k \neq \tilde{\phi}_k$  for some  $k \leq l < n$ . Thus the two functions  $g(\cdot)$  and  $\tilde{g}(\cdot)$  are not observationally equivalent.  $\square$

## C.2 Proof of Main Results

### C.2.1 Proof of Lemma 1

For simplicity of notation, denote  $q_n = (q_{j(i,1)}, \dots, q_{j(i,n)})$  and  $q_{n-1} = (q_{j(i,1)}, \dots, q_{j(i,n-1)})$ , which are truncated from  $q_i$  to the first  $n$  and  $n-1$  offers respectively. For any bounded function  $\psi(\cdot)$ ,  $E[\psi(Y_{i,j(i,n)}) | N_i = n, q_i, z, Y_{i,0} \geq t_{i,j(i,n)}]$  is bounded and identified whenever the conditioning event has positive probability. Therefore, it remains to show that  $E[\psi(Y_{i,0}) | N_i = n, q_i, z, Y_{i,0} \geq t_{i,j(i,n)}]$  is identified. Now, re-write

$$\begin{aligned} & E[\psi(Y_{i,0}) | N_i = n, q_i, z, Y_{i,0} \geq t_{i,j(i,n)}] P(N_i = n | q_i, z, Y_{i,0} \geq t_{i,j(i,n)}) \\ &= E[\psi(Y_{i,0}) | N_i > n-1, q_i, z, Y_{i,0} \geq t_{i,j(i,n)}] P(N_i > n-1 | q_i, z, Y_{i,0} \geq t_{i,j(i,n)}) \\ &\quad - E[\psi(Y_{i,0}) | N_i > n, q_i, z, Y_{i,0} \geq t_{i,j(i,n)}] P(N_i > n | q_i, z, Y_{i,0} \geq t_{i,j(i,n)}) \\ &= E[\psi(Y_{i,0}) | N_i > n-1, q_{n-1}, z, Y_{i,0} \geq t_{i,j(i,n)}] P(N_i > n-1 | q_{n-1}, z, Y_{i,0} \geq t_{i,j(i,n)}) \\ &\quad - E[\psi(Y_{i,0}) | N_i > n, q_n, z, Y_{i,0} \geq t_{i,j(i,n)}] P(N_i > n | q_n, z, Y_{i,0} \geq t_{i,j(i,n)}). \end{aligned}$$

The first equality follows from set inclusion and the last from Assumption 2. These quantities in the last expression are observed by focussing on the subset of patients that receive the sequence of offer types  $q_{n-1}$  and  $q_n$ . By assumption, these sequences of offer types is in the support of the sequence of offer types induced by  $J_i$ . Since  $P(N_i = n | q_i, z, Y_{i,0} \geq t_{i,j(i,n)})$  is identified and strictly positive,  $E[\psi(Y_{i,0}) | N_i = n, q_n, z, Y_{i,0} \geq t_{i,j(i,n)}]$  is identified. The marginal distributions of  $Y_{i,0}$  and  $Y_{i,j(i,n)}$  conditional on  $N_i = n, q_i, z$  and  $Y_{i,0} \geq t_{i,j(i,n)}$  are identified because the conditional expectations of  $\psi(Y_{i,0})$  and  $\psi(Y_{i,j(i,n)})$  are identified for any bounded function  $\psi$ .

### C.2.2 Proof of Lemma 2

For any  $k \leq n$ , Assumptions 1 and 2 imply that the observed probability that  $D_{i,j(i,1)} = D_{i,j(i,2)} = \dots = D_{i,j(i,k)} = 0$ , i.e.,  $N_i > k$ , can be re-written as equation (5.1). Observe that  $\zeta_k = \int_0^1 \varepsilon_D^k dv(\varepsilon_D; q_j, z)$  is identified for  $k \in \{1, \dots, n\}$  and that  $v(\cdot; q_j, z)$  is absolutely continuous by Assumption 3. Thus, the result follows from parts (i) and (ii) of Lemma 5. This concludes the proof of Lemma 2. If Assumption 4(i) holds, Lemma 4 imply that the function  $v'(\cdot; q_j, z)$  is identified in  $(0, 1)$ . This result will be used in the proof of Theorem 1.

### C.2.3 Proof of Theorem 1

**Identification of  $E[Y_{i,0} | \nu_{i,D} = \nu]$ .** For a given  $\nu \in (0, 1)$ , fix  $z$  such that there exists  $\varepsilon_D \in (0, 1)$  with  $v(\varepsilon_D; q_j, z) = \nu$ . Assumptions 1, 2 and 3 imply that for each  $k \leq n$ , we can write equation (5.2).  $E[Y_{i,0} | \nu_{i,D} = \nu]$  is continuous and integrable by Assumption 4(ii-iii). The hypotheses of Lemma 2 and Assumption 3 imply that the continuous function  $v'(\cdot; q_j, z)$  is identified in  $(0, 1)$  and so is  $E[Y_{i,0} | \nu_{i,D} = \nu]$  by Lemma 6 applied to  $F(\cdot) = v(\cdot; q_j, z)$ .

**Identification of  $E[Y_{i,j} | \nu_{i,D} = \nu, \varepsilon_{i,j,D} \geq \varepsilon, q_j]$ .** Assumptions 1, 2 and 3 imply that for each  $k \leq n$ , we can re-write the observed quantity  $E[Y_{i,j} \times 1\{N_i = k\} | q_j^k, z]$  as

$$\int_0^1 E[Y_{i,j} | \nu_D = v(x; q_j, z), \varepsilon_{i,j,D} \geq x, q_j] x^{k-1} (1-x) dv(x; q_j, z)$$

We will invoke Lemma 6 with  $F(\cdot) = v(\cdot; q_j, z)$ ,  $f(\cdot) = v'(\cdot; q_j, z)$  and

$$g(\nu_D) = \int_{v^{-1}(\nu_D; q_j, z)}^1 E[Y_{i,j} | \nu_D, \varepsilon_{i,j,D} = \varepsilon, q_j] d\varepsilon.$$

These functions are continuous and integrable by Assumption 4. By the conclusion of Lemma 6,  $\int_{v^{-1}(\nu_D; q_j, z)}^1 E[Y_{i,j} | \nu_D, \varepsilon_{i,j,D} = \varepsilon] d\varepsilon$  is identified. Thus,  $E[Y_{i,j} | \nu_{i,D} = \nu, \varepsilon_{i,j,D} \geq \varepsilon, q_j]$  is identified for all  $\nu_D \in (0, 1)$ ,  $\varepsilon_D \in (0, 1)$  such that  $\nu_D = v(\varepsilon_D; q_j, z)$  for some  $z$  in the support of its distribution.

### C.3 Donor Unobserved Heterogeneity

We extend our identification results to allow for donor heterogeneity  $\eta$  that is observed by agents but not by the econometrician. For donor  $j$ , patients observe both  $q_j$  and  $\eta_j$ , whereas the econometrician only observes the former. We modify equations (3.2) and (3.3) to depend on  $\eta$  explicitly. The outcome of patient  $i$  assigned organ  $j$  is  $Y_{i,j} = \hat{g}_1(q_j, x_i, \eta_j, \nu_{i,1}, \varepsilon_{i,j,1})$  and the acceptance rule is  $\hat{g}_D(q_j, x_i, \eta_j, z_i, \nu_{i,D}, \varepsilon_{i,j,D}) \in \{0, 1\}$ . As in the main text, we assume that  $\hat{g}_D$  is non-increasing in  $\nu_{i,D}$  and non-decreasing in  $\varepsilon_{i,j,D}$ . We also assume that it is non-increasing in  $\eta_j$  and normalize the distribution of  $\eta$  to be uniform on the unit interval. For simplicity, we fix  $t_{i,j} = 0$  and we omit  $x_i$  from the notation as it will be held fixed.

In addition to Assumption 1, we now require:

**Assumption 5.** *The random variable  $\eta_j$  is independent and identically distributed across  $j$ .*

The acceptance and rejection sets, which now depend on  $\eta_j$  are separated by the function

$$\epsilon(\nu_{i,D}, \eta_j, q_j, z) = \sup \left\{ \varepsilon_D \in [0, 1] : \hat{g}_D(q_j, \eta_j, z, \nu_{i,D}, \varepsilon_D) = 0 \right\},$$

where we follow the convention that the supremum of the empty set is 0. This function is non-decreasing in its first two arguments.

Throughout the argument, condition on observed donor type  $q_j$  and scarcity  $z$ . Given the unobservable  $\eta$ , consider the conditional probability that the donor will be rejected by a patient drawn from the (unconditional) population of patients. This probability is

$\pi(\eta; q_j, z) = \int_0^1 \epsilon(\nu, \eta, q_j, z) d\nu$ . Since  $\eta$  is a uniformly distributed random variable,  $\pi(\eta; q_j, z)$  is a random variable with cdf denoted by  $F_\pi(\cdot|q_j, z)$ .

Let  $R_k$  denote the event that a randomly drawn donor is consecutively rejected by the first  $k$  patients drawn from the (unselected) population of patients.

$$P(R_k|q_j, z) = \int \pi^k dF_\pi(\pi|q_j, z). \quad (\text{C.3})$$

The probabilities  $P(R_k|q_j, z)$  are data. We will use this equation to identify  $F_\pi(\cdot|q_j, z)$ .

We are going to exploit the fact that, conditional on observables, organs that are offered in later positions are adversely selected in terms of  $\eta_j$ . A complication is that both the number and type of patients who have previously rejected the organ induce selection on the unobserved donor type of the set of rejected organs that are offered to patients down the list. To simplify the argument, focus attention on offers for organs that were offered to and rejected by  $k$  observationally equivalent patients who have not received any other offer in the past. Formally, we will define  $K_{ij}$  as a random variable that is equal to minus one if some patient  $i' \neq i$  that received an offer for organ  $j$  before  $i$ , either accepted it—i.e.,  $D_{i'j} = 1$ —or had received a previous offer—i.e.,  $j \neq j(i', 1)$ . Otherwise,  $K_{ij}$  is the number of patients  $i'$  who received an offer for organ  $j$  before  $i$ . Let the type of an offer be summarized the pair  $\{q_j, k_{ij}\}$ .

Given the unobservable selectivity  $\nu$ , consider the conditional probability that the patient rejects a donor drawn from the (unconditional) population of donors with observable characteristic  $q_j$  and history  $k$ . This probability is

$$\rho(\nu; q_j, k, z) = \int_0^1 \epsilon(\nu, F_\pi(\pi|q_j, z), q_j, z) \frac{\pi^k}{\int_0^1 \tilde{\pi}^k dF_\pi(\tilde{\pi}|q_j, z)} dF_\pi(\pi|q_j, z) \quad (\text{C.4})$$

with cdf  $F_\rho(\cdot, q_j, k, z)$ . When  $k = 0$ , donors are not selected based on their unobserved  $\eta$ , so after the change of variables  $\eta = F_\pi(\pi|q_j, z)$ ,  $\rho(\nu; q_j, 0, z) = \int_0^1 \epsilon(\nu, \eta, q_j, z) d\eta$ . For positive  $k$ , the distribution of  $\eta$  is selected. Unobservably worse organs, i.e., those with low  $\pi$  due to low  $\eta$ , become relatively scarce. Because  $\rho(\nu; q_j, k, z)$  depends on the random draw  $\nu$ ,  $\rho(\nu; q_j, k, z)$  is a random variable. In the absence of donor unobserved heterogeneity,



$F_\rho(\cdot, q_j, k, z)$  is equal to  $v(\cdot, q_j, z)$  for all  $k$ . Let  $\{q_j, k\}^n$  be the set of offers consisting of  $n$  consecutive offers of type  $\{q_j, k\}$ . We can write an expression analogous to (5.1) for the probability of a randomly selected patient rejecting  $l$  consecutive offers from  $\{q_j, k\}^n$  as:

$$P(N_i > l | \{q_j, k\}^n, z) = \int_0^1 \rho^l dF_\rho(\rho, q_j, k, z). \quad (\text{C.5})$$

Because the probabilities  $P(N_i > l | \{q_j, k\}^n, z)$  are directly identified, this equation will be used to show identification of  $F_\rho(\rho, q_j, k, z)$ .

We are now ready to derive identification results analogous to those of the main text in a model with unobserved heterogeneity  $\eta$ .

### C.3.1 Identifying Conditional Expected Outcomes

Lemma 1 yields that the marginal distributions of  $Y_{i,j(i,n)}$  and  $Y_{i,0}$  conditional on  $N_i = n$ ,  $z_i = z$ ,  $K_{ij} = k$  and  $q_i$  are identified for all  $n \leq |q_i|$  such that  $P(N_i = n | q_i, k, z, Y_{i,0} \geq t_{j(i,n)}) > 0$ ,

$$\left( \{q_{j(i,1)}, k_{ij(i,1)}\}, \{q_{j(i,2)}, k_{ij(i,2)}\}, \dots, \{q_{j(i,n)}, k\} \right)$$

and

$$\left( \{q_{j(i,1)}, k_{ij(i,1)}\}, \{q_{j(i,2)}, k_{ij(i,2)}\}, \dots, \{q_{j(i,n-1)}, k_{ij(i,n-1)}\} \right)$$

belong to the support of the distribution of offer-types induced by the distribution of  $J_i$ .

### C.3.2 Identifying the Choice Model

We follow a similar argument to that of lemma 2 to identify  $F_\pi$  and  $F_\rho$  as an intermediate step to show identification of  $\epsilon(\cdot, \cdot, q_j, z)$  under a stronger version of Assumption 3:

**Assumption 6.** For each  $q_j$  and  $z$ , (i)  $\epsilon(\cdot, \cdot, q_j, z)$  has continuous positive derivatives with respect to its first two arguments in  $(0, 1)^2$ , (ii) for every  $(\nu, \eta) \in (0, 1)^2$ , there exist a pair of dominating functions  $\bar{\epsilon}_\eta(\cdot)$  and  $\bar{\epsilon}_\nu(\cdot)$ , integrable in the unit interval, such that  $\frac{\partial}{\partial \eta} \epsilon(\cdot, \eta', q_j, z) < \bar{\epsilon}_\eta(\cdot)$  on  $(0, 1)$  for every  $\eta'$  in a neighborhood of  $\eta$  and  $\frac{\partial}{\partial \nu} \epsilon(\nu', \cdot, q_j, z) < \bar{\epsilon}_\nu(\cdot)$  on  $(0, 1)$  for every  $\nu'$  in a neighborhood of  $\nu$ .

Similar to Assumption 3, Assumption 6 requires that there are no (interior) values of  $\nu_D$  for which the patient either accepts or rejects all organs of type  $q_j, \eta_j \in (0, 1)$  when faced with scarcity  $z$ . Moreover, it also requires that there are no (interior) values of  $\eta$  for which patient of unobserved type  $\nu_D \in (0, 1)$  either accepts or rejects all organs of type  $q_j, \eta$  when faced with scarcity  $z$ . Part (ii) allows us to obtain derivatives of  $\pi(\eta; q_j, z)$  and  $\rho(\nu; q_j, k, z)$  by differentiating under the integral sign.

**Lemma 7.** *If Assumption 6 holds, then (i)  $F_\pi(\cdot|q_j, z)$  is absolutely continuous on  $[0, 1]$ ,  $F_\pi(0|q_j, z) = 0$ ,  $F_\pi(1|q_j, z) = 1$ . (ii)  $F_\pi(\cdot|q_j, z)$  has a strictly positive and continuous derivative on  $(\pi(0; q_j, z), \pi(1; q_j, z))$ , (iii)  $F_\rho(\cdot|q_j, k, z)$  is absolutely continuous on  $[0, 1]$ ,  $F_\rho(0|q_j, k, z) = 0$ ,  $F_\rho(1|q_j, k, z) = 1$  and (iv)  $F_\rho(\cdot|q_j, k, z)$  has a strictly positive and continuous derivative on  $(\rho(0; q_j, k, z), \rho(1; q_j, k, z))$ .*

*Proof.* Assumption 6(i) implies that  $\pi(\cdot; q_j, z)$  is strictly increasing. By assumption 6(ii) and the dominated convergence theorem,  $\pi(\cdot; q_j, z)$  has a strictly positive and continuous derivative on  $(0, 1)$ . Theorem 2 in Villani (1984) implies that the inverse of  $\pi(\cdot; q_j, z)$  exists and is absolutely continuous. The inverse of  $\pi(\cdot; q_j, z)$  equals  $F_\pi(\cdot|q_j, z)$  since  $\eta$  is uniformly distributed. Because the domain of  $\pi(\cdot; q_j, z)$  is  $[0, 1]$ , the range of  $F_\pi(\cdot|q_j, z)$  is also  $[0, 1]$ . Monotonicity and absolute continuity imply  $F_\pi(0|q_j, z) = 0$  and  $F_\pi(1|q_j, z) = 1$ . The derivative of  $F_\pi(\cdot|q_j, z)$  at  $\pi \in (\pi(0; q_j, z), \pi(1; q_j, z))$  is the reciprocal of the derivative of  $\pi(\cdot; q_j, z)$  at  $F_\pi(\pi|q_j, z) \in (0, 1)$ ; thus, the derivative is positive and continuous. This concludes the proof of parts (i) and (ii). Parts (iii) and (iv) follow by the exact same arguments replacing  $\pi(\cdot; q_j, z)$  by  $\rho(\cdot; q_j, k, z)$ .  $\square$

**Lemma 8.** *If Assumptions 1, 2, 5 and 6 are satisfied, and  $\{q_j, k\}^n$  is in the support of the distribution of offer-types induced by  $J_i$ , then the Fourier-Legendre approximations  $s_{n-1}(F_\pi(\cdot|q_j, z), x)$  and  $s_n(F'_\pi(\cdot|q_j, z), x)$  are identified for each  $z \in (0, 1)$  and  $q_j$ . Similarly,  $s_{n-1}(F_\rho(\cdot|q_j, k, z), x)$  and  $s_n(F'_\rho(\cdot|q_j, k, z), x)$  are identified. In particular, if the hypotheses hold for all  $n$ , then  $F_\pi(\cdot|q_j, z)$ ,  $F'_\pi(\cdot|q_j, z)$ ,  $F_\rho(\cdot|q_j, k, z)$  and  $F'_\rho(\cdot|q_j, k, z)$  are identified.*

*Proof.* Assumptions 1, 2 and 5 imply that the observed probability that the first  $k$  offers made to observationally identical patients who have not received any previous offer is can

be written as in (C.3). Note that  $a_k = \int_0^1 \pi^k dF_\pi(\pi|q_j, z_i)$  is observed for  $k \in \{1, \dots, n\}$  and that  $F_\pi(\cdot|q_j, z)$  is absolutely continuous by Lemma 7 and has derivative  $F'_\pi(\cdot|q_j, z)$ . Similarly, the observed probability that an individual rejects  $l$  offers of type  $\{q_j, k\}$  can be written as equation (C.5). Observe that  $\zeta_l = \int_0^1 \rho^l dF_\rho(\rho|q_j, k, z_i)$  is identified for  $l \in \{1, \dots, n\}$  and that  $F_\rho(\cdot|q_j, k, z)$  is absolutely continuous by Lemma 7 and has derivative  $F'_\rho(\cdot|q_j, k, z)$ . Thus, the results follow by Lemmas 4 and 5.  $\square$

**Lemma 9.** *If Assumptions 1, 2, 5 and 6 are satisfied and  $\{q_j, k\}^n$  is in the support of the distribution of offer-types induced by  $J_i$  for all integers  $k = 0, 1, 2, \dots, n$  and  $n = 1, 2, \dots$ , then  $\epsilon(\cdot, \cdot, q_j, z)$  is identified in  $(0, 1)^2$  for each  $z$  and  $q_j$  in the support of the data. Therefore,  $P(D_{i,j} = 1 | \nu_{i,D} = \nu_D, \eta_j, q_j, z)$  is identified.*

*Proof.* Consider any closed interval  $I \subset (\rho(0; q_j, k, z), \rho(1; q_j, k, z))$ . Let  $S_n(F_\rho(\cdot|q_j, k, z), x) = \frac{1}{n} \sum_{m=0}^{n-1} s_m(F_\rho(\cdot|q_j, k, z), x)$ . For each  $n = 0, 1, 2, \dots$  define  $f_n$  as the solution to the problem  $\min_{g \in \mathcal{N}_n} \|S_{n|I} - g\|_\infty$ , where  $S_{n|I}$  is the restriction of  $S_n$  to  $I$  and  $\mathcal{N}_n$  is the set of non-decreasing  $n$ -Lipschitz functions  $I \rightarrow [0, 1]$ . The set is compact, so  $f_n$  exists. Let  $\tilde{f}_n(x) = n^{-1}((n-1)f_n(x) + x)$ . The strictly increasing function  $\tilde{f}_n(x)$  is  $I \rightarrow [0, 1]$ .

$$\|\tilde{f}_n - F_{\rho|I}\|_\infty \leq \|\tilde{f}_n - f_n\|_\infty + \|f_n - S_{n|I}\|_\infty + \|S_{n|I} - F_{\rho|I}\|_\infty,$$

where  $F_{\rho|I}$  is the restriction of  $F_\rho$  to  $I$ . By Lemma 7,  $F'_\rho(\cdot|q_j, z)$  is continuous, thus, it has a finite supremum norm. For all  $n > \|F'_{\rho|I}(\cdot|q_j, k, z)\|_\infty$ ,  $\|f_n - S_{n|I}\|_\infty \leq \|S_{n|I} - F_{\rho|I}\|_\infty$  because  $F_{\rho|I} \in \mathcal{N}_n$ . Thus,  $\|\tilde{f}_n - F_{\rho|I}\|_\infty \leq \|\tilde{f}_n - f_n\|_\infty + 2\|S_{n|I} - F_{\rho|I}\|_\infty$ . The first term is bounded by  $n^{-1}$  and, by lemma 3,  $\|S_{n|I} - F_{\rho|I}\|_\infty \rightarrow 0$ . Thus,  $\tilde{f}_n$  converges uniformly to  $F_{\rho|I}$ . By Theorem 2 in Barvinek et al. (1991),  $\tilde{f}_n^{-1}$  converges locally uniformly to  $\rho(\cdot; q_j, k, z)$ , the inverse of  $F_{\rho|I}(\cdot, q_j, k, z)$ , in interior of the image of  $F_{\rho|I}(\cdot|q_j, k, z)$ .  $\tilde{f}_n^{-1}$  is identified from  $\frac{1}{n} \sum_{m=0}^{n-1} s_m(F_\rho(\cdot|q_j, k, z), x)$  which is identified by Lemma 8. Thus,  $\rho(\nu; q_j, k, z)$  is identified for all  $\nu \in (0, 1)$ .

Rearranging equation (C.4),

$$P(R_k|q_j, z) \rho(\nu; q_j, k, z) = \int \epsilon(\nu, F_\pi(\pi|q_j, z), q_j, z) \pi^k F_\pi(d\pi|q_j, z). \quad (\text{C.6})$$

We will apply lemma 6 with  $\phi_k = P(R_k|q_j, z) \rho(\nu; q_j, k, z)$  for varying values of  $k$ ,  $g(\cdot) = \epsilon(\nu, \cdot, q_j, z)$ , and  $F(\cdot) = F_\pi(\cdot|q_j, z)$ . Lemma 8 states that  $F'_\pi(\cdot|q_j, z)$  is identified. Therefore, for every  $\nu \in (0, 1)$ ,  $\epsilon(\nu, \cdot, q_j, z)$  is identified in the open unit interval.  $\square$

### C.3.3 Identifying Selection on Unobservables

To obtain an identification result for expected outcomes analogous to Theorem 1, we need to strengthen Assumption 4:

**Assumption 7.** For each  $q_j$ , the function  $E[Y_{i,j}|\nu_D, \eta, \varepsilon_{i,j,D} \geq \varepsilon_D, q_j]$  is continuous in  $\nu_D$ ,  $\eta$  and  $\varepsilon_D$  for  $(\nu_D, \eta, \varepsilon_D) \in (0, 1)^3$ .

**Theorem 2.** Suppose that Assumptions 4, 7 and the hypotheses for Lemma 9 hold. Then, the quantities  $E[Y_{i,0}|\nu_{i,D} = \nu_D]$  and  $E[Y_{i,j}|\nu_{i,D} = \nu_D, \eta, \varepsilon_{i,j,D} \geq \varepsilon_D, q_j]$  are identified for all  $\varepsilon_D \in (0, 1)$ ,  $\eta \in (0, 1)$  and  $\nu_D \in (0, 1)$  such that there exists  $z$  in the support of its distribution with  $\epsilon(\nu_D, \eta, q_j, z) = \varepsilon_D$ .

*Proof.* Identification of  $E[Y_{i,0}|\nu_{i,D} = \nu_D]$  follows from Theorem 1 for a sequence of offers  $\{q_j, 0\}^n$  for any  $z$ . Now, consider the sequence of offers  $\{q_j, k\}^n$  for  $k \geq 0$ . The expression for the expected survival conditional on a transplant can be rearranged to yield:

$$\begin{aligned} & E[Y_{i,j} \times 1\{N_i = n\} | \{q_j, k\}^n, z] \\ &= \int_0^1 E[Y_{i,j} | \nu_{i,D} = F_\rho(\rho; q_j, k, z), \{q_j, k\}, z] \rho^{n-1} (1 - \rho) dF_\rho(\rho; q_j, k, z). \end{aligned}$$

As discussed in subsection C.3.1, the left-hand side of this equation is identified by Lemma 1. Let  $g(\nu) = E[Y_{i,j}|\nu_{i,D} = \nu, \{q_j, k\}, z]$ . This function is continuous and integrable over  $\nu$  by Assumptions 4(iii) and 7 and it is therefore identified by Lemma 6 with  $F(x) = F_\rho(x; q_j, k, z)$ . By the law of iterated expectations:

$$\begin{aligned} & E[Y_{i,j} | \nu_{i,D} = \nu_D, \{q_j, k\}, z] P(R_k | q_j, z) \\ &= \int E[Y_{i,j} | \nu_{i,D} = \nu_D, \eta = F_\pi(\pi | q_j, z), \varepsilon_{i,j,D} \geq \epsilon(\nu_D, F_\pi(\pi | q_j, z), q_j, z), q_j] \pi^k dF_\pi(\pi | q_j, z), \end{aligned}$$

where  $\epsilon(\cdot, \cdot, q_j, z)$  is identified by Lemma 9. Let

$$g(\eta) = E[Y_{i,j} | \nu_{i,D} = \nu_D, \eta, \varepsilon_{i,j,D} \geq \epsilon(\nu_D, \eta, q_j, z), q_j]$$

This function is continuous by Assumption 7, integrable over  $\eta$  by Assumption 6. Thus, it is identified by Lemma 6 with  $F(x) = F_\pi(x|q_j, z)$ . Therefore, the conditional expectation  $E[Y_{i,j} | \nu_{i,D} = \nu_D, \eta, \varepsilon_{i,j,D} \geq \varepsilon_D, q_j]$  is identified for all  $\varepsilon_D \in (0, 1)$ ,  $\eta \in (0, 1)$  and  $\nu_D \in (0, 1)$  such that there exists  $z$  in the support of its distribution with  $\epsilon(\nu_D, \eta, q_j, z) = \varepsilon_D$ .  $\square$

This result also implies identification of the analogous quantities for any bounded transformation  $\psi(\cdot)$  of  $Y_{i,0}$  and  $Y_{i,j}$ .

#### C.4 Dynamic Selection

The results in this subsection explicitly assume that  $Y_{i0}$  denotes survival. Therefore, we will assume that agent  $i$  may be assigned object  $j$  only if  $Y_{i0} > t_{i,j}$ . Using waiting time in the mechanism allows for selection in transplanted survival outcomes.

Our main result requires an additional mild restriction on the conditional distribution of  $Y_{i0}$ :

**Assumption 8.** *For any  $t > 0$ ,  $\log P(Y_{i0} \geq t | \nu_D)$  is a continuous function of  $\nu_D$  on the closed unit interval.*

One implication of this assumption is that if  $P(Y_{i0} \geq t) > 0$  implies  $P(Y_{i0} \geq t | \nu_D) > 0$  for all  $\nu_D \in [0, 1]$ . With this assumption, we show the identification in the presence of dynamic selection:

**Theorem 3.** *Suppose that Assumption 8 and the hypothesis of Theorem 2 hold, allowing for  $t_{i,j} > 0$ . Then, the probability  $P(D_{ij} = 1 | \nu_{i,D} = \nu_D, \eta, Y_{i0} \geq t_{i,j})$  and the expectation  $E[\psi(Y_{ij}) | \nu_{i,D} = \nu_D, \eta, \varepsilon_{i,j,D} \geq \varepsilon_D, Y_{i0} \geq t_{i,j}]$  are identified for any bounded function  $\psi(\cdot)$ , and all  $\varepsilon_D \in (0, 1)$ ,  $\eta \in (0, 1)$  and  $\nu_D \in (0, 1)$  such that there exist  $z$  in the support of its distribution with  $\epsilon(\nu_D, \eta, q_j, z) = \varepsilon_D$  and  $P(Y_{i0} \geq t_{i,j})$ .*

The argument is developed in two steps. In the first step, we identify the conditional distribution of  $\nu_D$  for agents that survive until time  $t$  (Lemma 11). The second step takes this

conditional distribution and combines it with the arguments that parallel those in Theorem 2.

Let  $h_t(v)$  be the cdf of  $\nu_D$  conditional on surviving until  $t$ :  $h_t(v) = \int_0^v \frac{P(Y_{i0} \geq t | \nu_D)}{P(Y_{i0} \geq t)} d\nu_D$ .

**Lemma 10.** *If Assumption 8 holds, then for every  $t$  such that  $P(Y_{i0} \geq t) > 0$ ,  $h_t(\cdot)$  is a strictly increasing function with a strictly positive and continuous derivative that maps the closed unit interval to itself.*

*Proof.* Note that  $h_t(0) = 0$  and  $h_t(1) = 1$ . Moreover, Assumption 8 implies that  $h'_t(v) = \frac{P(Y_{i0} \geq t | v)}{P(Y_{i0} \geq t)}$  is strictly positive and continuous.  $\square$

**Lemma 11.** *Suppose that the hypothesis of Theorem 2 hold. The function  $h_t(v)$  is identified for every  $t$  such that  $P(Y_{i0} \geq t) > 0$ .*

*Proof.* Let  $\{q_j, k\}$  be a donor-type that arrives at the same time time as patient  $i$ . Because the image of  $F_\rho(\cdot, q_j, k, z)$  is the unit interval (Lemma 7), for any  $\nu_D \in (0, 1)$  and  $z$ , there exists  $\varepsilon_D \in (0, 1)$  such that  $\nu_D = F_\rho(\varepsilon_D; q_j, k, z)$ . Theorem 2 implies that for every  $t \geq 0$ ,  $P(Y_{i0} \geq t | \nu_D) = E[1\{Y_{i0} \geq t\} | \nu_D]$  is identified. Thus,  $P(Y_{i0} \geq t)$  and, for all  $t$  such that  $P(Y_{i0} \geq t) > 0$ , the function  $h_t(v)$  is identified.  $\square$

### Proof of Theorem 3:

*Proof.* Take any  $\varepsilon_D \in (0, 1)$ ,  $\eta \in (0, 1)$  and  $\nu_D \in (0, 1)$  satisfying the stated hypotheses. Conditional on  $Y_{i0} \geq t$ , the random variable  $h_{i,D,t} = h_t(\nu_{i,D})$  is uniformly distributed and, by the properties of  $h(\cdot)$  stated in Lemma 10, the function  $\kappa_t(h_{i,D,t}, \eta_j, q_j, z) = \epsilon(h_t^{-1}(h_{i,D,t}), \eta_j, q_j, z)$  satisfies Assumption 6 when  $\epsilon(\nu, \eta_j, q_j, z)$  satisfies it: it has continuous and positive derivatives with respect of its first two arguments,  $\bar{\epsilon}_\eta(\cdot) \|h'_t(\cdot)\|_\infty$  is a dominating function for  $\frac{\partial}{\partial \eta} \kappa_t(\cdot, \eta', q_j, z)$  for  $\eta'$  in a neighborhood of  $\eta_j$ , and  $\epsilon_\nu(\cdot)$  is a dominating function for  $\frac{\partial}{\partial h} \kappa_t(h', \cdot, q_j, z)$  for  $h'$  in a neighborhood of  $h_{i,D,t}$ . Lemma 9 implies that,  $P(D_{i,j} = 1 | h_{i,D,t} = h_{D,t}, \eta_j, q_j, z, Y_{i0})$  is identified and Theorem 2 implies that  $E[\psi(Y_{i,j}) | h_{i,D,t} = h_{D,t}, \eta, \varepsilon_{i,j,D} \geq \varepsilon_D, q_j, Y_{i0} \geq t]$  is identified. The conclusion follows because  $h_t(\cdot)$  is invertible (Lemma 10) and identified (Lemma 11).  $\square$

## D Additional Figures and Tables

Table D.5: Top 10 offers: Balance

	Age (1)	Diabetes (2)	Female (3)	Weight (4)	Height (5)
log(1 + # Top 10 Offers in 2 Years)					
KDPI <= 50%	-0.0479 (0.0772)	0.00134 (0.00302)	-0.00158 (0.00277)	-0.269* (0.108)	0.0253 (0.0732)
KDPI > 50% or Missing	-0.0233 (0.0683)	-0.00427 (0.00294)	0.000269 (0.00276)	0.104 (0.101)	0.0137 (0.0819)
DSA FE, Year FE, and Blood Type FE	x	x	x	x	x
Control for Pediatric at Listing	x	x	x	x	x
CPRA Category Controls	x	x	x	x	x
F-test p-Value	0.499	0.267	0.787	0.037	0.828
Number of Observations	128949	127414	128949	127363	126619
R-Squared	0.026	0.022	0.074	0.038	0.034
Distribution of # Top 10 Offers in 2 Years					
Mean	16.92	16.97	16.92	16.91	16.88
Std. Dev.	22.86	22.92	22.86	22.82	22.79

Notes: \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$

The sample for all regressions is patients who registered between 2000 and 2008. Dependent variables are as indicated in the column headers. All regressions control for DSA fixed effect, registration year fixed effect, blood type fixed effect, an indicator for pediatric at registration, and indicators for CPRA = 0,  $20 \leq \text{CPRA} < 80$ ,  $\text{CPRA} \geq 80$ , and CPRA missing at registration. Standard errors, clustered by DSA, registration year, and blood type, are in parentheses. F-test tests against the null hypothesis that the coefficients on the instruments are zero.

Table D.6: Scarcity Instruments: Balance

	Age	Diabetes	Female	Weight	Height
	(1)	(2)	(3)	(4)	(5)
Log(1 + No. Donors)					
Patients Waited 0-1 years	-0.319 (0.331)	0.00271 (0.0125)	-0.00105 (0.0115)	0.151 (0.516)	-0.254 (0.328)
Patients Waited 1-2 years	0.135 (0.299)	-0.0129 (0.0117)	0.00164 (0.0109)	0.330 (0.457)	0.0594 (0.307)
Patients Waited 2-3 years	-0.256 (0.272)	0.000252 (0.0104)	0.0130 (0.00902)	-0.290 (0.397)	-0.0133 (0.269)
Patients Waited 3-4 years	0.286 (0.223)	0.0160 (0.00910)	-0.0272*** (0.00800)	0.114 (0.348)	0.109 (0.225)
Patients Waited 4-5 years	-0.0248 (0.153)	-0.0117 (0.00603)	0.0120* (0.00533)	-0.393 (0.220)	-0.212 (0.152)
Log(1 + No. Offers)					
Patients Waited 0-1 years	0.395* (0.195)	0.0165* (0.00817)	-0.00352 (0.00765)	0.301 (0.323)	0.350 (0.218)
Patients Waited 1-2 years	-0.0375 (0.215)	0.0000856 (0.00847)	-0.00111 (0.00764)	-0.228 (0.328)	-0.174 (0.228)
Patients Waited 2-3 years	0.0897 (0.213)	0.000332 (0.00817)	-0.00488 (0.00698)	0.300 (0.315)	0.0110 (0.223)
Patients Waited 3-4 years	-0.123 (0.196)	-0.0124 (0.00766)	0.0189** (0.00666)	-0.1000 (0.299)	-0.0956 (0.196)
Patients Waited 4-5 years	0.0748 (0.133)	0.0125* (0.00527)	-0.0130** (0.00475)	0.234 (0.197)	0.114 (0.132)
Year FE, DSA FE, and blood type FE	x	x	x	x	x
Control for Pediatric at Listing	x	x	x	x	x
CPRA Category Controls	x	x	x	x	x
F-test p-Value	0.319	0.166	0.201	0.555	0.692
Number of Observations	87205	87200	87205	86078	85500
R-Squared	0.025	0.021	0.076	0.036	0.038

Notes: \* p<0.05, \*\* p<0.01, \*\*\* p<0.001

The sample for all regressions is adult patients who registered on the waitlist between 1999Q4 and 2005Q4. Each regression is on patient level, where the dependant variable is the patient characteristics in the column header at registration. Each regression has five regressors indexed by  $k = 0, 1, 2, 3, 4$ , where the  $k$ th regressor for patient  $i$  is computed as the number of unique donors (offers) such that: the offer is made to patients who are in the same DSA as  $i$ , have the same blood type as  $i$ , and have waited the same number of years as  $i$ ; the offer is made between  $4k + 1$  and  $4k + 4$  quarters, inclusive, from the quarter when  $i$  registers (e.g. if  $i$  registers in 2002Q1, then the offer must be made between 2003Q2 and 2004Q1 for  $k = 1$ ). All regressions control for DSA fixed effect, registration year fixed effect, blood type fixed effect, an indicator for pediatric at registration, and indicators for CPRA = 0,  $20 \leq \text{CPRA} < 80$ ,  $\text{CPRA} \geq 80$ , and CPRA missing at registration. Robust standard errors, clustered by DSA, registration year, and blood type, are in parentheses. F-test tests against the null hypothesis that the coefficients on the five regressors are zero.



Table D.7: Robustness

	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
Realized Assignment	8.13	8.78	8.72	8.73	8.88	10.07	8.66	8.08	8.93	8.69
Random Assignment among										
All Patients	7.27	7.87	7.71	7.56	7.91	8.92	7.74	7.16	7.81	7.65
Transplanted Patients	7.60	8.23	8.09	8.12	8.31	9.38	8.09	7.65	8.43	8.19
No Choice	7.99	8.01	7.90	7.83	8.00	8.85	7.86	7.05	7.56	7.71
Optimal Assignment among										
Transplanted Patients	10.45	10.48	10.35	10.37	10.47	11.91	10.25	9.30	10.39	10.16
All Patients Based on Only Observables	8.74	9.51	9.42	9.29	9.59	10.95	9.39	8.71	9.69	9.42
All Patients	10.48	13.84	13.68	13.58	13.83	15.97	13.74	12.16	12.90	13.48
Box-Cox $\rho$										
Survival without Transplant	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.5	0.6	0.6
Survival with Transplant	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.7	0.6	0.6
Instruments										
# Past Donors		x			x	x	x	x	x	x
# Past Offers			x							
# Future Donors				x						
Donor Unobservables	x	x	x	x		x	x	x	x	x
Other Unobservables		x	x	x	x	x	x	x	x	x
Adding Cold Ischemic Time										x

Notes: Robustness of the results presented in Figure 4. The baseline specification is presented in column (2). The remaining specifications vary the instruments, the presence of  $\eta_j$ , or the Box-Cox shape parameters as indicated in the table.